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Abstract
The adverse effects of smoking have been widely promulgated for several
decades through several research studies, culminating in the hallmark Surgeon General’s
Report (United States Department of Health and Human Services [USDHHS], 2014). The
2014 Surgeon General’s Report (SGR) concluded that smoking leads to numerous
adverse effects in patients with cancer, including poor wound healing, increased postoperative pain, increased side effects from cancer treatment, and increased cancerspecific and all-cause mortality (USDHHS, 2014). However, extant literature is less well
defined regarding the effect smoking has on response to both cancer treatment and
treatment-related toxicities (USDHHS, 2014). Despite the benefits of smoking cessation
for all patients, there is also a paucity of data regarding the best way to most effectively
deliver tobacco cessation services to patients with cancer in the United States (US).
Additionally, in a healthcare environment that is increasingly challenged to provide
financially feasible services, the ability to maintain integral resources to offer
evidence-based, cost-effective tobacco cessation services to patients is also a key
consideration.
This compendium represents three manuscripts that contain distinct but related
areas of research related to individuals with lung cancer who smoke. The first manuscript
offers a literature review that outlines the interventions, outcomes and tobacco quit rates
of programs delivering tobacco cessation programs for cancer patients in the United
States (US). The second and third manuscripts detail quantitative studies that explore
whether current and former smokers may require additional second- and third-line
treatment as compared to the referent group of never smokers, and whether the groups of
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current and former smokers experience more treatment-related side effects as compared
to never smokers. Lastly, we will provide a preliminary cost analysis in the group of
current, former and never smokers who receive second-line and third-line chemotherapy.
By 1) exploring how to best deliver tobacco cessation services to patients with cancer
who smoke, 2) examining possible associations between tobacco use and treatment
progression and treatment toxicities, and 3) reviewing preliminary costs of second-line
and third-line chemotherapy across current, former, and never smokers, this compendium
will help clarify current gaps in literature, synthesize research findings, and provide a
preliminary basis on which specific areas for further research may be recommended.
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1

Introduction
Tobacco use is the leading preventable cause of premature death in the United
States (UDHHS, 2014). In the 54 years since the dissemination of the 1964 SGR which
established adverse outcomes from smoking, smoking and exposure to secondhand
smoke has caused over 20 million early US deaths (USDHHS, 2014). Although most of
these individuals were smokers, approximately 2.5 million non-smoking individuals also
died prematurely as a result from exposure to secondhand smoke during this same period
(USDHHS, 2014). In addition to be a causal factor for heart and lung disease, smoking is
also directly associated with over 17 types of cancers and numerous other diseases,
including macular degeneration, diabetes mellitus, and rheumatoid arthritis (USDHHS,
2014).
The economic burden of continued tobacco use is also profound, with over $300
billion spent in the US each year in direct and indirect costs for smoking-related illnesses
(Centers for Disease Control and Prevention, 2016). Despite the widespread adverse
impact of tobacco use on population health, and despite the significant associated costs,
tobacco companies continue to advertise smoking and tobacco use on a global basis. In
2015, cigarette companies spent $8.2 billion on cigarette advertising and promotional
materials (Federal Trade Commission, 2017), which equates to approximately $22.4
million dollars every day.
In individuals diagnosed with cancer who continue to use tobacco products
(cigarettes and non-cigarette products), ongoing dependence causes numerous adverse
effects, including impaired wound healing, post-operative complications, higher risks of
additional site primary cancers, and increased cause-specific and all-cause mortality
(Bjarnason et al., 2009; Vandersteen et al., 2013). Cigarette smoking is also associated
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with increased side effects from chemotherapy, radiation, and surgery in patients
receiving cancer treatment (USDHHS, 2014). However, less is known about the effects
of tobacco use on individual’s response to cancer treatment and treatment-related
toxicities (USDHHS, 2014). Due to the mounting evidence that patients who smoke after
a cancer diagnosis experience increased adverse outcomes compared to their
non-smoking counterparts, it is imperative that providers assess tobacco use status during
all healthcare encounters and deliver targeted tobacco cessation interventions to patients
who use tobacco products, particularly those suffering from tobacco use related illnesses.
Unfortunately, tobacco use may not be routinely assessed by oncology providers at
regular intervals during healthcare encounters, and tobacco cessation services are not
offered to patients on a regular basis (Gritz, Toll, & Warren, 2014; Keith et al., 2017).
Barriers to assessing tobacco use and providing tobacco cessation services for
patients who use tobacco persist across multiple contexts (Hanna, Mulshine, Wollins,
Tyne, & Dresler, 2013; Land, 2012; Warren et al., 2015), including patient, provider, and
health system/policy levels. Patient barriers include underlying personal characteristics
such as poverty or lack of medical insurance, mental illness or substance use disorder,
lack of self-efficacy to quit, stress, as well as lack of family support (Lucchiari, Masiero,
Botturi, & Pravettoni, 2016; Martinez, 2009; Wells et al., 2017). Provider barriers include
lack of efficacy and knowledge of how to help patients with cancer to stop smoking, and
lack of time to devote to smoking cessation efforts during office visits (Hanna et al.,
2013; Lucchiari et al., 2016; Warren & Ward, 2015; Weaver et al., 2012). Health system
and policy barriers include inadequate information technology systems to support
screening and services, lack of national standards requiring providers to deliver cessation,
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lack of internal policies by cancer centers to make cessation a standard of care, low
reimbursement rates for delivering cessation intervention, and limited insurance coverage
for cessation counseling and medications (Agency for Healthcare Research and Quality,
2012; Hanna et al., 2013). To overcome these barriers and address the multiple health
implications and economic strain of continued tobacco use, it is critical that (1) healthcare
researchers and administrators develop and implement evidence-based tobacco cessation
programs for patients with cancer; and that (2) healthcare providers systematically deliver
cessation services within the context of these programs.
To inform work towards achieving these critical priorities, this dissertation project
is designed to address three key research questions: 1) what is the most effective method
of delivering tobacco cessation services to patients with cancer? 2) what is the effect of
smoking status on short-term cancer treatment outcomes?, and 3) what is the effect of
smoking status on healthcare costs in patients with cancer (specifically, second-line and
third-line chemotherapy) during treatment? Better characterization about how to most
effectively deliver tobacco cessation services to cancer patients and the effects of
smoking status on cancer treatment and subsequent downstream healthcare costs may
provide the impetus for oncology centers and oncology providers to develop, implement
and sustain tobacco cessation services for their patients.
Theoretical Foundation
To measure the effectiveness of delivering tobacco cessation services to patients
with cancer, oncology centers must have the means to assess tobacco use, and deliver
tobacco cessation services. Assessing the quality and effectiveness of various delivery
methods is imperative to determine the best means by which to deliver outcome-based
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care. The Donabedian (1966) Quality of Care framework, one of the most widely used
frameworks for measuring quality, was chosen to guide the literature review. Although
most contemporary health care providers are familiar with the principles of quality care
assurance, the Quality of Care framework helped formulate outcomes assessment before
the concept held its position as a highly regarded health care paradigm and will be used to
as a framework for the literature review.
Three quality of care dimensions relate to heath care quality assessment in the
Donabedian (1966) framework: a) structure, b) process, and c) outcome. Structure relates
to the auspices under which care is delivered and may include the organization or people
delivering the care, while process relates to the intervention delivered, from a provider or
patient perspective. Outcome pertains to the impact of the health care on the individual
patient or population. Donabedian (1966) posits that in measurement of quality of care,
one must focus on the perspectives of the health care providers, as well as patients and
the health care system. The Donabedian (1966) model helped formulate this literature
review to provide a basis for evaluating the structure and process of each set of tobacco
cessation interventions delivered to patients with cancer across inpatient and outpatient
settings. Measureable outcomes are often the primary focus of health care practice, and
rightfully so, but perhaps equally important is to understand the nature and processes of
the delivered interventions in order to assess the efficacy and suggest improvements. The
interventions are discussed in the first manuscript.
While Donabedian’s (1966) model provides the theoretical foundation for the
literature review in manuscript one, the 2014 SGR (USDHHS, 2014) is used
synergistically to provide the justification and the basis for manuscripts two and three. In
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manuscripts two and three, quantitative analyses are used to explore the association
between smoking status and treatment progression, side effects and treatment costs. Used
in conjunction and synergistically, Donabedian’s (1966) model helps form the basis for
evaluation of crucial processes to facilitate optimal outcomes of smokers with cancer as
identified in the 2014 SGR.
The compendium manuscripts focus on three aspects of care related to patients
with cancer who continue to use tobacco: a) outcomes of tobacco cessation services
provided to patients with cancer in the US as measured by smoking cessation rates; b)
association of tobacco use with progression of cancer treatment as measured by
progression through first-line, second-line, and third-line treatments; and c) a comparison
of the cost of second-line and third-line treatment in a group of never, former and current
smokers.
Manuscripts
This dissertation contains three manuscripts. The first manuscript, a systematic
review of tobacco cessation services in oncology settings in the US, evaluates the effects
of tobacco cessation interventions for patients with cancer across inpatient and outpatient
settings in the US. Numerous patient/social, provider and health system barriers may
exist, such as lack of knowledge of how to most effectively deliver tobacco cessation
services to patients with cancer, or how to implement tobacco cessation services on a
system-wide basis. Lack of time in clinic, inadequate provider training or inadequate
provider resources may be barriers (Warren et al., 2015), as is lack of insurance coverage
for cessation services (Hanna et al., 2013). Due to the barriers which negatively impact
delivery of tobacco cessation services, we explored quit rate outcomes and reviewed
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structural program processes that may have affected whether these programs did or did
not work. Manuscripts two and three are based upon a retrospective data analysis of 233
patients with lung cancer, stratified by smoking status, at a southeastern
university-affiliated Cancer Center (CC). The second manuscript examines the
association between smoking status and progression through first, second and third-line
cancer treatment. The third manuscript examines the association between smoking status
and cost of second-line treatment in the same population. The compendium represents
three related manuscripts in which we assess outcomes and delivery of tobacco cessation
services, as well as treatment progression in a cohort of current, former and never
smokers, and costs of second-line and third-line chemotherapy in patients with cancer.
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Manuscript 1
Tobacco Cessation Interventions in Patients with Cancer:
A Systematic Literature Review
Abstract
BACKGROUND: Review of extant literature indicates there is a lack of measured,
effective tobacco cessation intervention services that show benefit of intervention over
usual care in the United States for tobacco users who have cancer. Lack of robust
interventions may relate to patient/social, provider, and/or system barriers.
METHODS: A systematic literature review was conducted to explore the content and
format of tobacco cessation interventions for individuals with cancer across multiple
settings in the United States (US). Outcomes were assessed by reviewing the
effectiveness of tobacco cessation services delivered to patients in programs in the US.
FINDINGS: The studies (n=11) varied by intervention and design. Although only one of
the studies 11 studies showed a statistically significant effect of intervention as compared
to the control group, the interventions varied in terms of duration and services offered. Of
the 11 studies, 9 provided results in the direction of benefit for the intervention group.
CONCLUSIONS: Most of the studies did not show significant intervention effects, but
lack of statistically significant effect may have been driven in some studies by study
design issues, such as small sample size, differences in cancer type and stage, lack of a
true control group or contamination of the control group, or the presence of self-inflated
smoking cessation rates. Patients with lung cancer who continue to smoke may represent
a particularly difficult to treat population in terms of smoking cessation. Further research
is needed to determine the best method of delivery of tobacco cessation services to the
population of patients with lung cancer who smoke.
KEYWORDS: Lung Cancer, Smoking, Tobacco Cessation, Cessation Services, Quit
Rates
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Introduction and Background
The adverse effects of continued smoking in patients diagnosed with cancer are
well documented, including increased post-operative complications and impaired wound
healing, higher incidence of side effects during cancer treatment, and increased overall
mortality (Bjarnason et al., 2009; Vandersteen et al., 2013). However, despite strong
evidence that tobacco cessation has a positive effect on long-term adverse outcomes,
(USDDS, 2014), in the oncology population, tobacco use by patients with cancer is still
prevalent. Some studies estimate that approximately 30%-40% of patients with head,
neck, and lung cancers who are smokers at diagnosis continue to smoke after being
diagnosed with cancer (Burris, Studts, DeRosa, & Ostroff, 2015).
To facilitate optimal outcomes in patients undergoing cancer treatment, in 2003,
the American Society of Clinical Oncology (ASCO) urged health care providers to assist
in eliminating the use of tobacco on a worldwide basis, including use among patients
with cancer, by assessing tobacco use status and urging cessation. Other key
organizations, such as the National Comprehensive Cancer Center Network, have
provided periodic guidelines and evidence-based rationale for tobacco cessation
treatment, positing that it is never too late for patients who have cancer to stop smoking
to improve overall health (National Comprehensive Cancer Network, 2017).
According to the NCCN (2017) guidelines, to effectively deliver tobacco
cessation services, providers are urged to assess smoking status and document nicotine
dependence and prior quit attempts, while assessing readiness to quit. If the patient
expresses a readiness to quit smoking within 4 weeks of the initial assessment, health
care providers are encouraged to initiate treatment. Evidence-based treatment consists of
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nicotine replacement therapy (NRT) in conjunction with behavioral therapy for 12 weeks,
or the medication varenicline and behavioral therapy for 12 weeks. The guidelines advise
providers to reassess the patient at 2-3 weeks and again at 12 weeks after starting tobacco
cessation treatment; if the patient remains smoke free at 12 weeks, he or she should be
reassessed at 6 and 12 months. If the patient has relapsed, retreatment with additional
counseling and pharmacotherapy should be provided. The guidelines published by the
NCCN (2017) mirror ASCO’s (2003) guidelines in which clinicians are advised to assess
tobacco use at every visit and provide counseling and pharmacological therapy to patients
who use tobacco.
Although the NCCN and ASCO tobacco cessation guidelines highlighted above
are well-delineated and based on evidence, many cancer patients still do not receive
comprehensive tobacco cessation services. Unfortunately, there are several barriers that
currently prevent the guidelines from being fully implemented. These barriers exist at the
patient, provider, and health care systems/policy levels. Patient barriers include
underlying demographics such as poverty or lack of medical insurance, mental illness or
substance use disorder, lack of self-efficacy to quit, stress, as well as lack of family
support (Lucchiari et al., 2016; Martinez, 2009; Wells et al., 2017). Provider barriers
include lack of efficacy and knowledge regarding patients with cancer, lack of knowledge
regarding how to effectively deliver tobacco cessation services, and lack of time to
devote to smoking cessation efforts during office visits (Hanna et al., 2013; Lucchiari et
al., 2016; Warren & Ward, 2015; Weaver et al., 2012). Health systems and policy barriers
include inadequate information technology systems to support screening and services,
lack of national standards requiring providers to deliver cessation services, lack of
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internal policies by cancer centers to make cessation services a standard of care, low
reimbursement rates for delivering cessation, and limited insurance coverage for optimal
cessation counseling and medications (Agency for Healthcare Research and Quality,
2012; Hanna et al., 2013).
Due in part to the barriers highlighted above, tobacco cessation interventions are
provided inconsistently in oncology centers. In a 2009 survey of 58 National Cancer
Institute (NCI)-designated centers, only 34 (58.6%) of the centers reported having
tobacco use treatment in place for their patients, while 12 (20.7%) of the centers had only
referral-based tobacco cessation programs in place; the remaining 12 centers (20.7%) did
not have tobacco cessation interventions in place (Goldstein, Ripley-Moffitt, Pathman, &
Patsakham, 2013). In a 2012 assessment of physician members of the International
Association of the Study of Lung Cancer Society (IASLC) (N=1,153) designed to
elucidate physician perceptions of tobacco use treatment and barriers, Warren et al.
(2015) reported that although most (92%) of the responding physicians (n=1,065)
believed that smoking in patients with cancer affected treatment efficacy, almost 60% of
the physicians (n=685) perceived that they were unable to be successful in getting
patients to quit. Only slightly over one-third (34%, n=398) of the IASLCS members
reported having received adequate training in tobacco use assessment and treatment. Only
42%, (n=487) reported actively treating patients with cancer for tobacco cessation “all or
most of the time” (Warren et al., 2015, p.1533). Due to the evidence indicating that
tobacco cessation services are not being provided consistently to patients with cancer, the
current literature review was conducted to evaluate the types of tobacco cessation models
that have been evaluated in oncology settings, as well as their related outcomes.
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A limited number of studies in the US have attempted to evaluate the type and
characteristics of tobacco cessation interventions that are most effective to help patients
with cancer quit smoking (Cooley, Lundin, & Murray, 2009; Warren et al., 2015). Nayan,
Gupta, and Sommer (2011) and Nayan, Gupta, Strychowsky, and Sommer (2013)
conducted two separate meta-analyses to synthesize evidence to document the
intervention effects on quit rates for smokers with cancer. Postulating that individual
small studies may not have enough power to demonstrate statistical significance, Nayan
et al. (2011) and Nayan et al. (2013) pooled data across multiple studies to determine the
overall pooled intervention effect and whether a statistically significant difference existed
in adult patients receiving tobacco cessation interventions across the pooled samples.
Nayan (2011) divided 8 randomized controlled trials (RCTs) into two groups – short
follow-up time (mean of 5 weeks) and longer follow-up time (6 months). Although no
statistically significant effects were seen in the group with shorter follow-up times, the
longer follow up pooled group included four studies. When one original study from 18
years prior was excluded (Gritz, 1993), the remaining 3 studies with the longer follow up
group (Duffy et al., 2006; Schnoll et al., 2003; Wakefield, Olver, Whitford, & Rosenfeld,
2004) showed a positive relative risk of intervention over usual care when pooled. The
three studies that showed a positive relative risk had populations with diverse types of
cancer and also delivered interventions that included pharmacological treatment plus
counseling (Nayan, 2011).
Two years later, Nayan (2013) combined 10 RCTs and 3 prospective cohort (PC)
studies to determine if the effects had changed from their previous (Nayan, 2011) study.
Although the authors noted a slightly more favorable odds ratio (OR) in the IT group
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versus UC, the results still did not reach statistical significance. However, there was a
positive effect on cessation interventions in the peri-operative setting (Nayan, 2013),
suggesting that patients with cancer who are undergoing surgery may be more receptive
and able to quit smoking in the hospital setting.
Based on the evidence from these meta-analyses, although there were not strong
statistically significant pooled results, the most positive interventions were noted in the
groups of peri-operative patients, and when the interventions provided pharmacological
plus behavioral counseling (Nayan et al., 2011; Nayan et al., 2013). However, a question
remains as to which specific interventions have the most significant impact on smoking
cessation rates in patients with cancer. To fill this gap in the evidence, the current study
was designed to identify tobacco cessation interventions that have been evaluated in the
US for patients with cancer; evaluate the content, format, and efficacy of various
interventions; and recommend optimal strategies for delivery of tobacco cessation and
future research needs, based on the available evidence.
Theoretical Framework
Donabedian (1966)’s Quality of Care framework was used as a model for the
literature review. Focusing on a) structure, b) process, and c) outcome, Donabedian’s
model was used to evaluate the structure and process of tobacco cessation services with a
comprehensive review of the context of care delivery in inpatient and outpatient settings,
as well as the intervention components and intensity, which was conceptually defined in
this literature review as the type of intervention delivered. Outcomes of the tobacco
cessation services were noted, as measured by tobacco quit rates. Utilizing the
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Donabedian (1966) model provided a systematic framework to guide the assessment of
tobacco cessation intervention processes in the oncology population.
Methods
Study Design
A systematic literature review was conducted to explore the format and content of
tobacco cessation interventions for individuals with cancer across multiple settings,
including hospitals, clinics and cancer centers and the associated effectiveness of
interventions on tobacco cessation rates. Studies selected for review were limited to the
US due to global variability of smoking cessation guidelines for patients with cancer,
differences in availability of tobacco cessation services between countries, and alternate
recommendations for cessation pharmacotherapy, such as cysteine-containing
medications and use of nortriptyline as a second-line cessation agent in Europe
(Christensen, Jekunen, Heinonen, Dalton, & Rasmussen, 2017; Masefield et al., 2016).
Search Methods
Articles were included in the review if the study was conducted in the US and
published in English, pertained to participants with cancer over the age of 18 years who
used tobacco, and reported tobacco cessation or quit rates. Exclusion criteria excluded
studies that focused on interactions of patient/family dyads or on patients who had
already quit smoking prior to the study. Studies designed to investigate the use of
electronic cigarettes for smoking reduction or cessation also excluded. Lastly, studies
were excluded that did not have a control group for comparison. A CINAHL Complete/
EBSCOhost search was conducted across 44 databases, including CINAHL Plus,
OVID/Medline, and PsycINFO. In addition, the PubMed database was searched as well
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as Google Scholar and the Cochrane Library (Tobacco Addiction and Special Populations
groups).
To conduct the search, keywords related to the population and disease process
(i.e., oncology patient, cancer patient) were combined with words that applied to
interventions (i.e., tobacco cessation, smoking cessation, cessation services) and
interventions or outcomes (e.g., quit rates, intervention, program, evaluation). The search
was performed using keyword search strategies with the assistance of a research librarian.
Articles that were not peer reviewed were excluded.
Search Outcome
Of the titles retrieved from CINAHL Plus, OVID/Medline, PsycINFO, and the
PubMed databases, 1,614 studies were reviewed. During the preliminary review of titles,
53 duplicate articles were present. Of the remaining 1,561 unique titles that were
scanned, with a review of the abstract if necessary, 59 articles met the inclusion criteria
and were extracted for full review. Of those, 48 articles were excluded because they did
not meet the inclusion criteria after closer review, leaving 11 articles that are presented in
the current study. A cross-reference review of bibliographies, Google Scholar, and the
Cochrane Library did not yield additional articles beyond those located during the initial
database search.
Quality Appraisal
Randomized controlled trials (RCTs) were evaluated using the Critical Appraisal
Skills Programme Randomized Controlled Trials Checklist (2015), a standardized,
11-item questionnaire that provides a tool for standardized evaluation of RCTs.
Quasi-experimental studies were assessed using the Critical Appraisal Skills Programme
Case Cohort Study Checklist (2015), a standardized 12-item questionnaire that provides a
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tool for standardized evaluation of cohort studies. When using this tool for an evaluation
of studies, most of the components are evaluated on a dichotomous basis. Affirmative
scores on both tools, marked with a “yes” answer, address salient questions related to the
reviewed studies to discern a quality study. Although the affirmative responses on the
tools contain subjectivity, in general the greater number of affirmative answers indicates
a higher quality of study. For purposes of this review, the affirmative “yes” items were
summed and reported by the author. Scores resulting from the Critical Appraisal Tool
ranged from 10 to 11 on the 11-item scale for the RCTs and 11 to 12 on the 12-item scale
for the quasi-experimental studies, with higher scores indicating higher quality.
Results
The studies included in the literature review (N=11) are described in Table 1.
Eight of these studies were randomized controlled trials (RCTs) (Duffy et al., 2006;
Griebel, Wewers, & Baker, 1998; Gritz et al., 1993; Ostroff et al., 2014; Schnoll et al.,
2010; Schnoll et al., 2005; Schnoll et al., 2003; Stanislaw & Wewers, 1994) and three of
the studies utilized a quasi-experimental design. In each of the three quasi-experimental
studies, a historical control group received usual care (UC), followed sequentially by a
group that received intervention treatment (IT) (Browning, Ahijevych, Ross, & Wewers,
2000; Gosselin et al., 2011; Park et al., 2011). Eight of the studies were conducted
primarily in an outpatient clinic setting (Browning et al., 2000; Duffy et al., 2006;
Gosselin et al., 2011; Gritz et al., 1993; Park et al., 2011; Schnoll et al., 2010; Schnoll et
al., 2005; Schnoll et al., 2003), while three studies were carried out primarily in an
inpatient setting (Griebel et al., 1998; Ostroff et al., 2014; Stanislaw & Wewers, 1994).
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The studies included participants with varied primary sites of malignancy. Eight
of the studies focused primarily on participants with head, neck, and lung cancers
(Browning et al., 2000; Duffy et al., 2006; Gosselin et al., 2011; Gritz et al., 1993;
Ostroff et al., 2014; Park et al., 2011; Schnoll et al., 2005; Stanislaw & Wewers, 1994),
while three studies included patients with other cancers, such as gynecologic, breast,
prostate, colorectal and urological sites (Griebel et al., 1998; Schnoll et al., 2010; Schnoll
et al., 2003).
Interventions Delivered
The studies were categorized according to tobacco cessation intervention
components, using the current NCCN (2016) guidelines, which establish counseling in
conjunction with pharmacological therapy and subsequent follow-up support as key
components of a comprehensive smoking cessation intervention. Researchers for three
studies reported interventions of counseling with follow-up support but without
pharmacological therapy (Griebel et al., 1998; Gritz et al., 1993; Stanislaw & Wewers,
1994). In the remaining eight studies (Browning et al., 2000; Duffy et al., 2006; Gosselin
et al., 2011; Ostroff et al., 2014; Park et al., 2011; Schnoll et al., 2010; Schnoll et al.,
2005; Schnoll et al., 2003) patients were offered counseling, pharmacological therapy,
and some component of follow-up support as interventions, although the follow up
support varied in timing and intensity.
Intervention: Counseling, Follow-up Support, No Pharmacological Treatment
Three RCTs tested interventions consisting of counseling and follow-up support
without pharmacological therapy. In a prospective, two-group RCT of smokers with
cancer who were hospitalized for surgery, Griebel et al. (1998), initially included a
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sample of 36 patients (IT: n=18, UC: n=18) who were randomly assigned to each group.
Eight patients were dropped from the study: a) due to lack of a phone connection for
follow-up (n=4), b) results indicating benign histologic tissue rather than malignancy
(n=3), or c) the patient was noted to be deceased by the six-week follow-up visit (n=1).
Of the remaining study participants (n=28), IT patients (n=14) received the intervention
of a nurse-managed minimal smoking cessation intervention of 20 minutes of counseling
during post-operative recovery, written literature, and five weekly 10-minute telephone
contacts after discharge. UC patients (n=14) received no specific intervention, although
smoking cessation literature was available to the patients. Follow up at the 6-week clinic
visit of the 28 completing participants showed that 3 of the 14 (21%) participants in the
IT group were abstinent at 7-day point prevalence, and 2 of the 14 (14%) participants in
the UC group were abstinent. All 5 of the participants reporting abstinence were
biochemically confirmed negative for tobacco as defined by a saliva cotinine of ≤14
ng/mL Although the sample size was too small to conduct an inferential statistical
analysis, a change in the direction of difference was noted, with a 33% relative difference
and a 7% absolute difference in intervention over usual care for the 7-day point
prevalence abstinence at 6 weeks. The authors also noted that participants in the IT group
on average reduced the number of cigarettes more than the UC group (x̅ = 18.7, SD = 7.9
vs x̅ 12.1, SD 8.4, t(28) = 2.15, p < 0.05) (Griebel et al., 1998).
Gritz et al. (1993) also examined the effect of smoking cessation intervention on
cessation rates in a prospective RCT of 186 newly-diagnosed patients with 114
completers (IT: n=58; UC: n=56) with a first occurrence of primary squamous cell
carcinomas of the oral cavity, pharynx and larynx who had reported smoking in the last
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year. Seventy-two patients did not complete the study for the following reasons: death
(n=33); progressive illness which impeded participation in the study (n=4); declined
further participation in the study (n=16); lost to follow up (n=14); initial advice not
delivered by the provider (n=4); or determined ineligible due to patient inability to read
or write (n=1). Providers who received the training session subsequently provided
tailored counseling and written materials, a contracted “quit date,” along with six
“booster sessions” to patients in the IT group (Gritz et al., 1993, p. 263). The UC group
received basic counseling only. Gritz et al. (1993) assessed three smoking cessation
outcomes: a) if the patient ever quit (abstinent for 48 consecutive hours or longer at any
time during the 12-month follow-up period), b) point prevalence abstinence (for 48 hours
or longer) at the time of the 1, 6, and 12-month interviews, and c) continuous abstinence
from smoking at 1, 6 and 12-month follow-up. After 12-month follow up, 91.4% of the
IT group and 89.3% of the UC group reported ever quitting, with a point prevalence of
ever quitting as 69% in the IT group and 78.6% in the UC group. Continuous abstinence
was reported as 63.8% in the IT group, and 76.8% in the UC group (Fisher’s Exact test p
= 0.318.), with an 89.6% rate of positive cotinine validation. A contamination of the
control condition was noted, since providers delivered cessation advice in both the IT and
UC groups. Self-report of smoking cessation was validated by urine cotinine (Gritz et al.,
1993). Major limitations to the study include the loss of more than one third of their
participants, and the contamination of the UC group due to providers treating patients in
both groups (Gritz et al., 1993).
Stanislaw and Wewers (1994) conducted a pilot RCT of 26 patients (IT: n=12,
UC: n=14) with primarily head and neck cancer (80%, n=21) who were hospitalized for
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surgical treatment to determine the effect of a nurse-delivered smoking cessation
interview on short-term abstinence in the oncology population. They included adult
patients who had reported continuous use of tobacco for at least one year prior to the
study, further stipulating that the tobacco use would equal or exceed 10 cigarettes a day
with each cigarette containing at least 0.5 mg of nicotine to meet inclusion criteria.
Patients randomized to the IT group received post-operative nurse-delivered smoking
cessation advice, consisting of three consecutive visits daily for a duration of 20-30
minutes, while participants in the UC group received smoking cessation that varied
according to the health care provider delivering the intervention. Six of the 14 UC
patients (42.9%) and 9 of the 12 IT group patients (75%) reported abstinence at 5 weeks
post-discharge (p<0.1), and self-report of cessation was verified by saliva cotinine
analysis. Although the results of the study did not demonstrate statistically significant
efficacy due to the small sample size (of 126 patients screened, only 28 met the study
criteria), the effect of a standardized smoking cessation intervention for hospitalized
surgical patients was explored (Stanislaw & Wewers, 1994).
Intervention: Counseling, Pharmacological Therapy, and Follow-up Care
The remaining eight studies included counseling, pharmacological therapy, and
one or more components of follow-up care, although the follow-up care varied in
intensity and timing. The study with the shortest post-intervention follow-up (Gosselin et
al., 2011) is summarized first.
Gosselin et al. (2011) conducted a non-randomized quasi-experimental study of
patients with head and neck cancer designed to evaluate the effects of smoking cessation
interventions in 179 oncology patients (IT: n= 81, UC: n=98) following a 1-hour training
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session. Participants in the IT group (n=81), seen in clinic from July 2007 to August
2007, received “enhanced cessation” using best practices of the 5As (ask, advise, assess,
assist, arrange) and varenicline as first-line therapy. Participants in the UC group (n=98)
were seen between May 2007 and June 2007 and received no targeted interventions,
although the authors noted that participants in the usual care group may have been
advised to quit smoking. Of the 179 study participants, only slightly over half (63%,
n=112) completed the 1-month follow up interview. Quit rates were analyzed using two
methods: they were analyzed at the one-month follow up for each group based on the
sample size, and they were calculated for each sample based on the assumption that those
lost to follow-up had resumed smoking (intent-to-treat). The IT group had a quit rate of
14% compared to 13% of the UC group (this includes those who did not return for the
one month follow up); the p value was not reported for quit rate outcomes. Assessment of
smoking cessation was by self-report (Gosselin et al., 2011). Limitations of the study
include a short follow up time of one month, which may have been inadequate to
effectively assess the intervention, as well as a high dropout rate for participants, with
only 63% completing the one-month follow up interview (Gosselin et al., 2011).
Browning et al. (2000) conducted a quasi-experimental study in a surgery clinic
of patients with cancer who had smoked daily for one year or longer and were
undergoing surgical resection. The participants were not randomized, but they received
the intervention or usual care during 5-month data collection time periods. Of the 179
new patients who were screened, only 25 participated (IT: n= 14, UC: n=11). A
nurse-delivered intervention, based on the Agency for Health Care Policy and Research
(AHCPR Smoking Cessation Guideline (Fiore, 1998), was delivered to IT group patients
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utilizing the “4A’s” (ask, advise, assist, arrange, with no mention of the 5th A,
assessment). In addition to smoking cessation counseling, IT participants were strongly
encouraged to start dual therapy with NRT (applying a 21 mg patch every day for 8
weeks), and bupropion (150 mg twice daily, starting the week prior to therapy). UC
patients were advised by the physician to quit smoking. Patients in the IT group were
contacted 10-14 days after the quit date or during their hospitalization after surgery to
provide support. Abstinence rates confirmed at 6 months were not statistically significant;
the 6-month quit rates were 71% for the IT group compared to 55% for the UC group
(p=0.383). Smoking cessation was measured by self-report and confirmed with carbon
monoxide testing. The authors noted small sample size as a limitation and suggested that
larger scale studies over a longer time frame would be beneficial in order to recruit more
participants (Browning et al., 2000).
Duffy et al. (2006) conducted a prospective RCT study from 2003 to 2006 in four
outpatient clinics in 184 randomly assigned patients (IT: n=93, UC: n=91) with head and
neck cancer. Positing that underlying comorbidities of problem drinking, and depression
are interrelated, the authors set out to address the interrelationship between the
comorbidities. Every participant received a comprehensive, 45-minute nursing
assessment to review self-reported smoking, alcohol misuse, and/or depression
conditions, combined with brief counseling. In addition, participants in the IT group
received a tailored intervention to address smoking, alcohol use, and depression,
including pharmacological therapy for smoking cessation (NRT and bupropion), while
UC participants (n=91 received “enhanced usual care” of counseling (Duffy, 2006, p.
2204). Of the 93 IT subjects, 77 completed all aspects of the intervention, resulting in a

24

TOBACCO CESSATION INTERVENTIONS IN PATIENTS

17% attrition rate of the IT group. (The UC group did not have an attrition rate because
UC consisted of a one-time assessment and referral). Participants were included in the
study if they reported smoking, alcohol misuse, and/or depression conditions. Of the 136
participants who smoked, there was a statistically significant difference in smoking
cessation after the intervention (47% in the IT group quit compared with 31% in the usual
care group who quit, p <0.05). In a subanalysis among the smokers who reported
depression and/or alcohol misuse (versus those participants who smoked only), the quit
rates were higher in the IT group (48%) versus the UC group participants (26%, p <
0.05). One major limitation, however, is that patients’ self-reports of smoking cessation
were not verified by biochemical testing in the study. (Duffy et al., 2006).
In an RCT of 185 hospitalized patients (IT: n=96; UC: n=89) with newly
diagnosed cancer scheduled for surgical resection, Ostroff et al. (2014) tested an
intervention of “scheduled reduced smoking” (SRS) (Ostroff, 2014, p. 738) combined
with “best practices” (Ostroff, 2014, p. 738), defined by the authors as cessation
counseling and pharmacotherapy. Scheduled Reduced Smoking (SRS), a technique in
which smokers gradually increase the intervals between cigarettes, had been
demonstrated in two prior trials of non-oncology smokers to be an effective tool to quit
smoking. Participants were eligible if they smoked at least 8 cigarettes per day within the
past week and were awaiting surgical treatment no less than 7 days from study entry. The
authors randomized participants by computerized permuted-block after stratifying
participants according to daily cigarette consumption (greater than 20 cigarettes per day
and less than 20 cigarettes per day). IT group patients (n=96) received SRS and BP, while
UC patients (n=89) received “best practices” alone. The primary outcome was 7-day
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point prevalence, evaluated at 6 months after hospitalization. Smoking status was
obtained by self-report verified by cotinine analysis. At 6-month follow-up, the 7-day
point prevalence rates were reported as 32% for both UC and IT groups. The secondary
outcome was assessed at hospital admission, with 24-hour point prevalence abstinence,
verified by carbon monoxide breath test, and at 3 months post-hospitalization verified by
salivary cotinine testing. At 3-month follow-up, the 7-day point prevalence rates were
reported as 34% for the UC group and 36% for the IT group (p=.88, OR 0.9, 95% CI: 0.5,
1.8). At 6-month follow-up, the 7-day point abstinence rates were 32% for both the UC
group and the IT group (p= 1.0, OR =1.0, 95% CI: 0.5, 2.0). Smoking status was selfreported and confirmed by carbon monoxide testing (Ostroff et al., 2014). Limitations of
the study include the short time of the intervention during hospitalization.
In a year-long (2008-2009), prospective cohort, non-randomized study of 49
patients (IT: n=32; UC: n=17) with suspected or known thoracic malignancy, Park et al.
(2011) examined the feasibility of a 12-week smoking cessation program that combined
counseling with varenicline. The IT group (n=32) received a 12-week program with
counseling delivered by a certified Tobacco Treatment Counselor and varenicline 1 mg
twice daily, compared to the UC group (n=17). The UC participants’ care was not
explicitly described by the authors. The authors also measured emotional support
assessments at baseline and follow up, using the Medical Outcomes Study survey, as well
as depression and anxiety at baseline and follow up with the Hospital Anxiety and
Depression Scale. Participants in the IT group received a median of 9 counseling
sessions, and 50% of the intervention participants completed the full varenicline course.
At 12-week follow up, 7-day point prevalence tobacco abstinence rates were 14.3% in the
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control group versus 34.4% in the intervention group (odds ratio 3.1, 95% CI: 0.6, 16.6, p
= 0.18), which was not statistically significant. Cessation was obtained by self-report, and
validated by saliva cotinine analysis (Park et al., 2011). One major limitation, as noted
above, is that care received by the UC group was not specified, and the sample size was
small.
Schnoll et al. (2010) conducted a double-blind, placebo-controlled randomized
trial that assessed the effect of bupropion for 246 patients (IT: n=114; UC: n=132) with
cancer who smoked at least two cigarettes a day on average, stratifying patients according
to depressive symptoms a priori. While all participants received five counseling sessions
and 8 weeks of transdermal nicotine replacement therapy, patients were randomized to
either 9 weeks of placebo (UC), or bupropion (IT). The primary outcome was 7-day point
prevalence of tobacco abstinence at weeks 12 and 27 weeks. Analysis was based on
intent-to-treat, with those lost to follow-up presumed to be smokers. There was no
statistically significant benefit of the IT group over the UC group at 12 weeks, with
reported abstinence rates of 27.2% for patients receiving bupropion and 24.2% for
patients receiving placebo. At week 27, abstinence rates were 18.4% for bupropion and
17.4% for placebo. Abstinence of smoking was verified by cotinine analysis (Schnoll et
al., 2010). One limitation was a relatively small sample size, especially as compared to
general population trials for bupropion.
Schnoll et al. (2005) designed a RCT to test an intervention of
cognitive-behavioral therapy (CBT) in 109 patients (IT: n=52; UC: n=57) with cancer,
using the Cognitive-Social Health Information-Processing model (C-SHIP). Patients were
randomized to either usual care (operationally defined as “general health education”
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[GHE] (n=57), which provided information of harmful effects of smoking, or the
intervention, CBT (n=52). All participants received an 8-week supply of transdermallydelivered NRT. Follow-up at 1 month demonstrated no statistical significance of IT over
UC, with 47.3% of the UC group versus 44.9% of the IT group reporting 30-day point
prevalence abstinence at 1 month (p=0.845, OR = 1.0, 95% CI: -.5, 2.5). At 3-month
follow-up, 39.2% of UC versus 43.2% of IT reported abstinence at 3 months (p=.083, OR
=.8, 95% CI: .3, 2.1), with no statistically significant difference between the groups.
Smoking was assessed by self-report without biochemical verification of smoking
cessation (Schnoll et al., 2005). Limitations include a relatively small sample size and
smoking cessation by self-report.
Schnoll et al., (2003) tested a physician-based intervention using the Agency for
Healthcare Research and Quality’s “5A”s (Ask, Advise, Assess, Assist and Arrange), in
conjunction with NRT in an RCT of 432 patients (IT: n=215, UC: n=217) with cancer
who smoked one or more cigarettes in the past 30 days prior to study entry. The patients
in the IT group (n=215) received advice to quit following the 5As, as well as NRT.
Participants in the UC group (n=217) received usual care; however, the authors noted that
all of the participants may have been provided with quit advice. The 7-day point
prevalence abstinence was assessed at 6 and 12 months in patients with cancer.
Follow-up was provided at subsequent medical visits, but it is not clear from the reported
study design when or how frequently the medical visits occurred. All patients were
contacted at 6 and 12 months to assess smoking abstinence. At 6 months, in the UC
group, 11.9% patients reported abstinence versus 14.4% of IT patients (p =0.27). At 12
months, 13.4% of patients had quit smoking, with 13.6% in the UC group versus 13.3%
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of patients in the IT group reporting abstinence (p=0.52), with no statistically significant
difference between the groups. Smoking cessation was by self-report without
biochemical verification. Limitations include the possibility of the UC group receiving an
intervention, and smoking cessation by self-report (Schnoll et al., 2003).
Demographic Components
The studies included in this literature review implemented experimental and
quasi-experimental designs to test smoking cessation interventions in smokers with
cancer. Four types of participant characteristics that may affect the effectiveness of an
intervention are discussed below.
Smoking Dependence
Smokers who are heavily addicted to nicotine products may have more difficulties
quitting smoking. The Fagerström Test for Nicotine Dependence (FTND) is a validated
instrument that relies on patients’ self-report of smoking behaviors and is used to assess
patients’ dependence on tobacco (Etter, 2008; Heatherton, Kozlowski, Frecker, &
Fagerström, 1991). The FTND instrument is scored from 0-10, with a score range of 5-7
indicating moderate tobacco dependence, while a score of ≥8 indicates a high dependence
on tobacco. FTND scores were assessed and reported in seven of the studies (Browning
et al., 2000; Gritz et al., 1993; Ostroff et al., 2014; Park et al., 2011; Schnoll et al., 2010;
Schnoll et al., 2005; Stanislaw & Wewers, 1994), while three of the studies provided
some components of the FTND scores, such as time to first cigarette of the day (Gosselin
et al., 2011; Griebel et al., 1998; Schnoll et al., 2003). FTND scores were not addressed
in one study (Duffy et al., 2006).
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Smoking Environment
Living with other smokers may hinder patients’ success due to continued nicotine
exposure and psychological effects (Manning et al., 2016), as well as lead to
false-positive results on cotinine testing (American Society of Clinical Oncology, 2012).
Researchers in five of the studies (Browning et al., 2000; Griebel et al., 1998; Park et al.,
2011; Schnoll et al., 2003; Stanislaw & Wewers, 1994) assessed and reported the
smoking environment of the participants, while the other studies did not report this
assessment.
Population Diversity
Most studies included primarily White participants (72.5% -100% White). In
addition, some studies had either incomplete race information on patients or did not
report ethnicities of participants.
Self-Report of Smoking Cessation Status
Smoking status is often under-reported by smokers due to guilt, stigma, and
shame (Warren & Ward, 2015; Weiss et al., 2016). Accordingly, self-report of smoking
without biochemical verification is often inaccurate. While it is unlikely that a participant
would report continued smoking if he or she had quit, self-report of smoking cessation
can lead to inaccurate results, as participants may report that they quit smoking when
they did not. Salivary cotinine or carbon monoxide testing are confirmed as reliable,
chemically validated methods to verify smoking cessation (Hanna et al., 2013; Mantler,
Irwin, & Morrow, 2012). Four of the 11 studies used self-report only as an indication of
smoking status (Duffy et al., 2006; Gosselin et al., 2011; Schnoll et al., 2005; Schnoll et
al., 2003), which is a limitation that may have led to inaccurate inflation of quit rates.
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Direction of Effects Observed
Of the 11 studies in the literature review, three studies lacked sufficient sample
sizes to report p-values (Gosselin, 2011; Griebel, 1998; Stanislaw & Wewers, 2004).
Only one study (Duffy, 2006) reported statistically significantly different quit rates of the
intervention over the control group, but the smoking status was self-reported and thus, the
accuracy of quit rates was unclear. Most (n=9) of the studies showed higher improvement
and a positive direction of effects (although not statistically significant) in quit rates for
the intervention group compared to the control group.
Discussion
The studies included in the literature review varied by intervention type and study
design. Eight of the studies (Browning et al., 2000; Duffy et al., 2006; Gosselin et al.,
2011; Ostroff et al., 2014; Park et al., 2011; Schnoll et al., 2010; Schnoll et al., 2005;
Schnoll et al., 2003) included components of counseling, pharmacological therapy and
follow-up assessments consistent with NCCN (2015) guidelines, while three studies
(Griebel et al., 1998; Gritz et al., 1993; Stanislaw & Wewers, 1994) provided intense
counseling and follow-up support. Only one study (Duffy, 2006), reported a statistically
significant effect of the intervention on smoking status (p< 0.1), but the smoking status
was self-reported by the participants. The remainder of the studies did not demonstrate
statistically significant effects of the interventions compared to usual care. In two recent
studies that reviewed tobacco cessation services in the US and Europe, Nayan et al.
(2013) and Nayan et al. (2011) also noted the lack of effect reported by the individual
studies and pooled the studies in two meta-analyses to compare the effect of the
programs. In neither analysis did the authors find a strong statistically significant
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difference when smokers with cancer received tobacco cessation interventions over a
control group receiving usual care in the meta-analyses (Nayan et al., 2011; Nayan et al.,
2013). However, the authors noted in both studies that there was a positive direction of
change in the groups that had longer follow-up time periods, and in the groups that
received pharmacological therapy plus counseling. Additionally, in the Nayan et al.,
(2013) study, a positive direction of change was observed in the peri-operative group,
suggesting that patients undergoing surgery may be more receptive and able to quit
smoking.
In our literature review, an examination of the specific intervention components
and intensity of cessation programs that may have influenced the effects of tobacco
cessation services indicate several factors may have contributed to the lack of efficacy of
interventions. Each of the studies tested different interventions: pharmacotherapy alone,
counseling alone, or pharmacotherapy, counseling plus follow up support (Browning et
al., 2000; Duffy et al., 2006; Gosselin et al., 2011; Ostroff et al., 2014; Park et al., 2011;
Schnoll et al., 2010; Schnoll et al., 2005; Schnoll et al., 2003), while other studies
included strictly counseling and follow up support (Griebel et al., 1998; Gritz et al., 1993;
Stanislaw & Wewers, 1994. Additionally, some participants in the usual care groups
received robust “usual care,” potentially contaminating the control conditions. Gritz et al.
(1993) noted evidence of contamination that occurred when medical advisement meant
only for the intervention group (establishing a quit date and discussing withdrawal
symptoms) was also received by some usual care group participants, thereby providing a
partial intervention to the usual care group. Another example of optimal care deemed
“usual care” was noted in Ostroff et al. (2014), where the usual care group received “best
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practices” care, or evidence-based standard of care, including counseling and NRT. Duffy
et al. (2006) noted that “enhanced usual care” (p.2204) was provided in which all
participants received a 45-minute nursing assessment to evaluate self-reported smoking,
alcohol problems, and depression; participants also received brief counseling and were
referred for smoking cessation, psychiatry, or alcohol treatment. In other studies, such as
in Park et al. (2011), usual care was not well defined and may have varied across the
patient population. Thus, across many of the studies, the lack of a true control group and
variation in intensity of usual care cessation services may have made it difficult to detect
intervention effects. More robust results may be observed if studies are conducted in
more “real world” clinical venues where usual care tobacco cessation services may be
lacking.
The lack of racial diversity was also apparent during review of the studies.
Although most of the studies involved primarily White participants (greater than 80%
average in seven studies), data from the Centers for Disease Control (2015) indicates that
Black men had the highest rate of all types of cancer from 1999-2013 at 500 cases per
100,000 in 2013 and had the highest rate of lung and bronchus cancer from 1999-2013.
Black Americans may have more challenges to tobacco cessation including more
exposure to and targeting by smoking advertisements, and may benefit from culturally
tailored programs (Wallen, Randolph, Carter-Pokras, Feldman, & Kanamori-Nishimura,
2014). Overall, the disproportionate number of minorities represented in the studies may
lead to lack of generalizable results (Coughlin, Matthews-Juarez, Juarez, Melton, & King,
2014).
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Only 7 of the 11 studies included biochemical validation of tobacco use status.
The only study that demonstrated a statistically significant benefit for IT group
participants compared to UC (Duffy et al., 2006) did not confirm self-reported tobacco
cessation using biochemical verification. The lack of biochemically-verified cessation
may inflate the cessation reports of individuals who reported quitting. Biochemical
validation helps to ensure precision and accuracy in assessment of tobacco cessation
outcomes, and should be used consistently (Gorber, Schofield-Hurwitz, Hardt, Levasseur,
& Tremblay, 2009).
Lastly, the continued use of tobacco in patients who have been diagnosed with a
tobacco-related cancer represents a particularly unique challenge. Although a cancer
diagnosis is associated with higher quit rates within 2 to 4 years of the diagnosis, patients
who already have chronic smoking-related diseases at diagnosis, such as emphysema,
have a lower rate of quitting (Lucchiari et al., 2016). When patients do express a desire to
quit smoking, they may perceive a lack of support or counseling from their health care
provider (Lucchiari et al., 2016). Additional factors may contribute to decreased quit
rates and a higher rate of smoking recidivism, including age (younger smokers may be
more likely to return to smoking after a surgery), as well as mental illness and lack of
support (Lucchiari et al., 2016).
Limitations
This literature review did not include studies conducted outside of the US.
Expanding the literature search beyond the US may have helped determine if there were
more effective processes for implementing tobacco cessation services world-wide. Also,
one reviewer confirmed the results of the literature search, which could have led to error.

34

TOBACCO CESSATION INTERVENTIONS IN PATIENTS

The period of review was through 2017, and additional studies may have been published
since this time.
Conclusions
The main purpose of this literature review was to identify published reports of
tobacco cessation services in the US for patients with cancer; evaluate the content,
format, and efficacy of these interventions; and make recommendations for the
implementation of future services based on the findings from these studies. According to
the most recent NCCN tobacco cessation guidelines (National Comprehensive Cancer
Network, 2017), all cancer patients who smoke should be provided with comprehensive
tobacco cessation services that include the following components: (a) behavioral
counseling, (b) pharmacotherapy, and (c) close follow-up at 2 weeks and 12 weeks with
consideration of follow-up at 6 and 12 months for relapse with retreatment as needed.
Although the studies demonstrated use of one or more components of the
recommendations, only one showed a statistically significant benefit of IT versus UC
(Duffy, 2006). Nine of the studies showed finding in the direction of benefit associated
with the group who received services. Lack of statistical significance across the studies
may have been driven by factors such as insufficient sample size, lack of a true control
group, inflated self-reported cessation in both the control and intervention groups, or
perhaps the interventions were not feasible.
Oncology patients who continue to smoke after a diagnosis of cancer may be
particularly refractory to traditional cessation interventions. Assessment of barriers as
well as counseling to enhance inherent self-efficacy may be beneficial. Due to the high
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rate of recidivism of smokers in general, targeted intervention with regular follow up
contact would likely be beneficial (Chang, Braith, Hitsman, & Schnoll, 2017).
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Table 1. Intervention: Counseling, no pharmacological treatment, follow-up support
Author,
Year

Dates
of
Study

Study
Population/
Primary
Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality:
Follow-up
support

Griebel et
al. (1998)

NR

28 (14 IT,
14 UC);
Gyn 21%,
breast 18%,
GI 14%,
thoracic
14%,
urologic
14%,
neurologic
11%,
head/neck
7%

Hospital
(postoperative)

One-time 20minute
smoking
cessation
intervention
delivered by
advanced
practice
nurse
certified in
cessation
counseling,
and written
booklet from
the
American
Cancer
Society on
tobacco
cessation

None

Five weekly 10minute telephone
contacts for 5
weeks after
discharge

Assessment
of Nicotine
Dependence
and
verification
of smoking
cessation
Nicotine
dependence
assessed
(reported
mean of years
smoked,
cigarettes per
day and time
to first
cigarette of
the day, but
Fagerström
scores not
reported;
Self-report
verified by
saliva
cotinine

Outcome
measures

Findings

CASP Score
(affirmative
answers/
Total points)

7-day point
prevalence
was
assessed at 6
weeks at
first clinic
visit after
surgery

At 6 weeks, 7-day
point prevalence
demonstrated 3 of the
14 IT patients were
abstinent versus 2 of
the 14 UC patients
were abstinent; all 5
participants reporting
abstinence verified by
saliva cotinine as nonsmoking (≤14 ng/mL).
P values not reported
on the 7-day point
prevalence. Change
noted in the direction
of difference, with a
33% relative difference
and a 7% absolute
difference in
intervention. IT
group’s mean change
score showed a
reduction in cigarette
consumption over UC.
Chi-square analysis
results: x̅ = 18.7, SD =
7.9 vs x̅ 12.1, SD 8.4, t
(28) = 2.15, P < 0.05;
limited by small
sample size.
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Author,
Year

Dates
of
Study

Study
Population/
Primary
Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality:
Follow-up
support

Assessment
of Nicotine
Dependence
and
verification
of smoking
cessation

Outcome
measures

Findings

CASP Score
(affirmative
answers/
Total points)

Gritz et
al. (1993)

NR

96 (50 IT,
46 UC);
patients
with newly
diagnosed
SCC of
oral cavity,
pharynx
and larynx

Hospitalbased
medical
and
dental
clinics

Initial
advice
session by
physicians
who had
completed a
2-hr
training
session

None

Six “booster
sessions” (p.
263) were
integrated into
the 6 monthly
medical visits
after treatment,
and 3 booklets
reinforcing
cessation. 6
reminder
postcards were
mailed in
conjunction
with the
“booster”
sessions

Fagerström
scores
reported.
Cessation
and
readiness to
quit
assessed.
Cessation
was by selfreport
validated by
urine
cotinine.

Three
cessation
outcomes
reported:
a) ever quit
(48-hr
point
prevalence
during 12month
follow up)
b) 48-hr
point
prevalence
at 1, 6 and
12-month
follow-up,
c)
continuous
abstinence
[CA]
(abstinent
at 1-,6-,
and 12months

Outcomes:
a) ever quit: 1 month
80% IT, 79.8% UC;
6 months 84.3% IT,
82.6% UC; 12
months 91.4% IT,
89.3% UC.
b) 48-hour pt prev at
1 month 69.4% IT,
76.2% UC; 6 months
71.4% IT, 6 months
71.4% IT, 73.9%
UC; 12 months
69.0% IT, 78.6%
UC. Continuous
abstinence (CA) at 1
month 69.4% IT,
75.0 UC; at 6
months, 64.3% IT,
71.0 UC; 12 months
63.8% IT, 76.8%
UC.
CA reported as
Fisher exact test
between IT and UC
group P = 0.318. No
significant
intervention effect;
authors noted
contamination of
control condition.
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Author,
Year

Dates
of
Study

Study
Population/
Primary
Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality:
Follow-up
support

Assessment
of Nicotine
Dependence
and
verification
of smoking
cessation

Outcome
measures

Findings

CASP Score
(affirmative
answers/
Total points)

Stanislaw
and
Wewers
(1994)

NR

N = 26 (14
in UC, 12
in IT).
Head and
neck
(80%),
breast
cancer
(8%),
prostate
cancer
(8%),
cervical
cancer
(4%)

Hospitalized
surgical
oncology
patients

3 hospital
counseling
sessions
delivered
by
oncology
clinical
nurse
specialists/
certified
smoking
cessation
facilitators;
included
audio tape
of
relaxation
exercises

None

Five weekly
phone calls

Fagerström
mean 5.66 ±
2.14 (UC)
and 5.00 ±
1.826 (IT).
Self-report
of cessation
followed by
saliva
cotinine
confirmation

5 weeks
after
discharge
at first
clinic visit;
point
prevalence
not
reported/
discussed

75% of intervention
group participants
(n=12) were
abstinent compared
to 43% of the UC
group (n=14) at 5week follow-up (x2 =
2.735, df = 1,
p <.10, although
small sample size
does not permit
conclusion of
efficacy
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Table 2. Intervention: Counseling, pharmacological therapy, and follow-up support
Author, Year

Dates of
Study

Study
Population/
Primary Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality: Followup support

Assessment of
Nicotine
Dependence and
verification of
smoking
cessation

Outcome
measures

Findings

CASP Score
(affirmative
answers/
Total points)

Browning
et al.
(2000)

NR

25 (14 IT, 11
UC); NSC
lung cancer
patients

Surgic
al
clinic,
urban,
tertiar
y

NRT,
bupropion

10-14 days after
quit date or
during postsurgery
hospitalization,
whichever was
first, and 5 visits
after

Self-reported
and expired
carbon
monoxide;
mean
Fagerström
dependence
for both
groups was 6

6-month
abstinence

At 6 months postsurgery, 71% for
IT group and 55%
for the UC group
(x2 = 0.762, df =1,
p = 0.383). No
statistical
differences, but
small sample size

11/12

Duffy et al
(2006)

20002003

N=184, 93 IT,
91 UC; head
and neck,
larynx,
oropharynx

Four
hospit
al
clinics

Nursedelivered
smoking
cessation
intervention
at
consultation
visit with
written
educational
materials re:
smoking
cessation
Cognitive
behavioral
therapy, 9-11
sessions of
telephone
counseling;
CBT
workbook

NRT and/or
bupropion.
Of 93 IT
group
patients, 33
were
prescribed
medication
for smoking
cessation or
depression

Ongoing (9-11
sessions of
telephone
counseling)

Fagerström
scores not
assessed;
smoking
status by
self-report

6-month
assessment of
remaining
participants
(n=154). If not
currently
smoking at 6month
assessment, pt
was
considered to
have quit.
Transient
cessation
attempts not
considered
quitting.

6-month survey;
47% smoking
cessation rate in
the IT group as
compared to
“enhanced usual
care (31%), p <
0.05). intervention
not beneficial if
treating
depression/ETOH
or smoking alone,

11/11

but if treated for
comorbid
smoking and
depression, inc.
cessation.
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Author, Year

Dates of
Study

Study
Population/
Primary Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality: Followup support

Assessment of
Nicotine
Dependence and
verification of
smoking
cessation

Outcome
measures

Findings

CASP Score
(affirmative
answers/
Total points)

Gosselin et
al. (2011

May
through
August
2007

N=179, 81 IT
group, 98 in UC
group; patients
with head and
neck cancers

Clinic

Fagerström
cores not
assessed;
smoking
cessation by
self-report

Quit rates
assessed at 1month followup survey

112 patients
completed 1-month
follow up survey
reported quit rates.
14% of the IT group
quit, 13% of the UC
group quit.

11/12

NR

N=185 (96 IT,
89 UC);
Thoracic (34%),
head and neck
(10%), urology
(20%)

Presurgical

Varenicline
first line
therapy or
NRT or
bupro-pion.
Only 31% of
IT pts
received
medication
NRT

Support call
within 10 days
after clinic visit

Ostroff et
al. (2014)

Delivered by
staff with
standardized
1-hr training
session on
cessation
counseling
and pharmacotherapy
Counseling by
oncology
nurses
certified as
tobacco
treatment
specialists
5 individual
counseling
sessions; 2
phone sessions
prior to
surgery, 1 inperson session
in hospital and
2 counseling
calls after
discharge

Two counseling
calls after
discharge in
conjunction with
the intervention,
but no follow-up
after the month
after hospital DC

Fagerström
score assessed;
mean of 4.7 (IT)
and 5.2 (UC);
self-report of
cessation
verified by CO
testing

7-day point
prevalence at 6
months post
hospitalization;
secondary
outcomes
assessed at
hospital
admission and 3
months posthospitalization

7-day point
prevalence at 6
months post
hospitalization;
secondary outcomes
assessed at hospital
admission and 3
months posthospitalization. At 3month follow-up, 7
day point prev 36%
IT and 34% UC,
(p=.878, OR 0.944,
95% CI; 0.490,
1.816). At 6-month
follow-up, 7 day
point prev rates 32%
for IT and UC groups
(p= 1.0, OR = 1.028,
95% CI: 0.525,
2.012). Lack of
treatment effect. Pts
with thoracic cancer
over other sites more
likely to be abstinent
at 3 months (OR
=2.16, CI: 1.164.183, p = .022)
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Author, Year

Dates of
Study

Study
Population/
Primary Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality: Followup support

Assessment of
Nicotine
Dependence and
verification of
smoking
cessation

Outcome
measures

Findings

CASP Score
(affirmative
answers/
Total points)

Park et al.
(2011)

January
2008 to
August
2009

49
(32 IT, 17 UC);
thoracic

Thoraci
c
oncolog
y and
thoracic
surgery
clinics

Clinician
initiated,
varenicline

Counseling
delivered by
a certified
Tobacco
Treatment
Counselor;
initially at
baseline visit
or by phone
within 48 hrs
of enrollment

IT group
participants
completed a
median of 9
counseling
sessions and had a
median of 88
minutes of
counseling

Fagerström test
for Nicotine
Dependence
used;
Biochemical
(salivary
cotinine
analysis) or
expired air
carbon
monoxide test if
on NRT

7-day point
prevalence at 2
weeks and 12
weeks

10/12

Schnoll et al.
(2003)

Dec
1990May
1992

N = 432 (n=217
IT, 218 UC);
Stage I-II cancer
(any type), stage
III-IV breast,
prostate,
testicular cancer
or lymphoma

Outpt
cancer
clinics

5As: Ask,
Advise,
Assess, Assist,
Arrange

NRT

Cessation progress
assessed at
medical visits
after counseling,
but not clearly
delineated when
follow-up was
provided

Fagerström not
reported;
cessation by
self-report

7-day point
preva-lence at 6
months, 12
months

At 2 weeks, 7-day
point prevalence =
28.1% in the IT
group versus 14.3%
in the UC group
(OR=2.35, 95% CI =
0.44-12.64, p = 0.32.
At 12-week followup, 34.4% IT vs.
14.3% in control
group (OR = 3.14,
95% CI = 0.59-16.62,
p = 0.18)
7-day point
prevalence at 6
months, 12 months;
at 6 months, 13.2% of
patients reported
abstinence, with no
significance between
the groups. In the UC
group, 11.9% patients
reported abstinence
versus 14.4% of IT
patients who reported
abstinence (p =0.27).
At 12 months, 13.4%
of patients had quit
smoking, with 13.6%
in the UC group
versus 13.3% of
patients in the IT
group reporting
abstinence (P=.52).
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Author, Year

Author,
Year

Study
Population/
Primary Site of
Malignancy

Setting

Modality:
Counseling

Modality:
Pharmacological

Modality: Followup support

Assessment of
Nicotine
Dependence and
verification of
smoking
cessation

Outcome
measures

Findings

Schnoll,
2005

NR

N = 109; head
and neck

N=
109;
head
and
neck

NRT

Four
counseling
sessions,
including one
in-person
counseling
session of 90
minutes

At 1 and 3 months
post-treatment,
participants were
called for a 90minute counseling
session and
“booster sessions”
(p. 2) of 20-30
minutes

Fagerström
used; cessation
was by selfreport

30-day point
prevalence at 1
month and 3
months

Schnoll,
2010

20022008

N = 246 clinic
patients;
Head and neck
or lung (32%),
breast (21%),
prostate (15%),
lymphoma
(9%), colorectal (5%),
kidney,
pancreas, or
liver (4%), GU
(3%),
esophageal
(3%), other 5%)

Clinic

5 counseling
sessions for all
participants (3
in person, 2 by
phone) from
trained
smoking
cessation
counselor.

NRT (all
participants,
plus
bupropion
(IT only) or
placebo (UC
only)

Follow up after
initial counseling
at week 3 and
three additional
counseling
sessions at weeks
5, 7 and 9

Average
Fagerström
score was 3.2
(SD 1.2, range
1-5),

7-day point
prevalence
abstinence at
week 12 (end of
treatment) and
week 27 (6
months post quit
day).

Asked participants if
they had smoked a
cigarette, even a puff,
in last 30 days. Quit
rates at 1-month
assessment: 44.9% of
the IT group vs.
47.3% of the UC
group versus reported
abstinence (odds ratio
[OR]= 1.065, 95%
confidence interval
[CI] = -.450, 2.518).
At 3 months, 43.2%
of IT 39.2% of UC
reporting abstinence
(OR =.821, 95% CI,
.327, 2.066).
7-day point
prevalence abstinence
at week 12 (end of
treatment) and week
27 (6 months post
quit day): at 12
weeks,
abstinence rates were
27.2% for IT and
24.2% for UC; at
Week 27, 18.4% for
IT and 17.4% for UC
(Odds Ratio [OR]
=1.36, 95% CI, 0.384.81, p = .64. No
main effect of
bupropion over
placebo on abstinence
(p=.64)

CASP Score
(affirmative
answers/
Total points)
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Figure 1. Flow diagram illustrating the search strategy used to conduct the systematic
review
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Manuscript 2
Association Between Tobacco Use and Short-Term Clinical Treatment Outcomes in
Patients with Lung Cancer: A Retrospective Data Analysis
Abstract
BACKGROUND: While the effects of tobacco use in lung cancer patients are associated
with adverse effects including increased post-operative complications, increased side
effects and increased cancer-specific and all-cause mortality, fewer studies link the effect
of short-term effects of smoking in patients undergoing treatment for lung cancer. This
retrospective data analysis was conducted to determine if there was an association
between smoking status and progression of first-, second-, and third-line treatment
(indicating treatment failure at each line), as well as treatment-limiting side effects, in a
population of patients in a southeastern university-affiliated Cancer Center (CC).
METHODS: A retrospective data analysis of participants at the CC (N=202) was
conducted to determine if patients who were current smokers at diagnosis progressed
through first-, second-, and third-line treatment more rapidly than patients who had either
formerly or never smoked. Major side effects were also noted in the same population.
Treatment progression was operationalized as progression from first-line to second-line
and/or third-line treatment due to failure of one of the treatments to provide cure or
remission. Side effects which affected further cycles of cancer treatment were also
assessed as an outcome.
FINDINGS: Compared to a referent group of never smokers, former smokers had 5.7
times the odds of being in the “no treatment progression” group (p =.02), and current
smokers had 2.5 times the odds of being in the “no treatment progression” group,
although not statistically significant (p = .18), When the model was repeated to only
include current and former smokers with current smokers as the referent group, former
smokers had 2.3 times the odds of being in the no treatment progression group than
current smokers, although the results did not reach statistical significance (p =.16).
CONCLUSION: Findings in this study did not support our hypothesis that current
smokers would progress more frequently through first-, second-, and third-line treatment
when compared to never smokers. The unexpected finding that the referent group of
never smokers was more likely to require subsequent lines of second- and third-line
therapy correlates with several theories, including emerging literature that suggests that
never smokers may experience a different disease trajectory than former or current
smokers. Alternately, decreased odds of treatment progression in current smokers may
not be indicative of improved health outcomes, but may instead reflect current smokers’
medical frailty, resulting in a truncated course of treatment. This exploratory analysis was
limited due to the inability to quantify disease progression. Further research with an
adequately powered population sample, measuring treatment progression in conjunction
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with disease progression, is needed to determine reasons that patients may stop treatment
early or why they progress through multiple lines of treatment.
KEYWORDS: Lung Cancer, Smoker, Chemotherapy, Treatment, Treatment Progression,
Disease Progression, First-Line Treatment, Second-Line Treatment, Third-Line
Treatment
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Introduction and Background
Over 230,000 individuals in the United States (US) will be diagnosed with lung
and bronchus cancer in 2018, and an estimated 154,000 will die from the disease
(American Cancer Society [ACS], 2018a). Cancer of the lung and bronchus causes more
deaths than any other type of cancer, accounting for approximately 35% of all cancer
deaths in 2018 (ACS, 2018). Although risk factors for lung and bronchus cancer include
environmental exposures and secondhand smoke, as well as genetic susceptibility in
certain individuals, cigarette smoking is linked to about 80-90% of lung and bronchus
cancers (Malhotra, Malvezzi, Negri, La Vecchia, & Boffetta, 2016; United States
Department of Health and Human Services [USDHHS], 2014). In individuals who
smoke, cigarettes (including the consumption of low-tar or menthol cigarettes) are
particularly harmful when compared to other methods of nicotine delivery, such as
chewing tobacco, snuff, or electronic devices, because cigarette smoke contains over 60
known or suspected carcinogens (ACS, 2018, USDHHS, 2014). In fact, over time,
changes in cigarette composition and design over time have resulted in an increase in the
carcinogenicity of cigarette smoke (SGR, 2014).
In patients with cancer who continue to smoke cigarettes following diagnosis,
smoking is associated with increased overall mortality and a higher risk for additional
primary cancers, as well as adverse side effects of cancer treatment in a broad spectrum
of patients (USDHHS, 2014). Although the association between smoking and adverse
long-term effects is clear, much less is known about the smoking’s effect on treatment
progression and side effects. Specifically, to date, although there is mounting evidence
that tobacco use may adversely affect short-term outcomes in patients with cancer by
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decreasing treatment efficacy and increasing treatment side effects, few studies have
demonstrated a causation between smoking and short-term cancer treatment outcomes in
patients with cancer (USDHHS, 2014). Thus, this retrospective data analysis will be
conducted to review the possibility of smoking’s effect on treatment-limiting side effects
and treatment progression.
In addition to numerous poor health outcomes in patients who smoke, the cost
burden of tobacco-related cancers is substantial. In 2014, there were an estimated
461,295 annual tobacco-related hospitalizations in the US, with a cost of $8.2 billion (Tai
et al., 2018). Over $87 billion was spent in the US in 2014 on health care related to
cancer, while patients and their families spent $3.9 billion on out-of-pocket costs,
including premiums, deductibles, and copayments for their cancer care (American Cancer
Society Action Network, 2017). Often, the highest proportion of the costs are paid as
deductibles by the patient within two or three months of diagnosis for screening and/or
diagnosis of their lung cancer (American Cancer Society Cancer Action Network, 2017),
encumbering the patient with a substantial financial burden early in the course of the
disease. Despite the consistently accumulating evidence regarding health-related and
financial implications of smoking, tobacco use persists, and continues to exert substantial
financial and health-related burdens on individuals worldwide.
Lung cancer is divided into two main groups based on histology: non-small cell
lung cancer (NSCLC) (National Cancer Center Network [NCCN], 2018), and small cell
lung cancer (SCLC). NSCLC, the most common type of lung cancer, accounts for
approximately 85% of lung cancers (NCCN, 2018); it includes adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma (ACS, 2018). The 5-year survival rate
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for people with stage IA NSCLC is approximately 92%, compared to less than 1% for
individuals with Stage IVB NSCLC (ACS, 2018). Individuals who never smoked almost
always have adenocarcinoma, a cancer which typically develops in the lung periphery
(Piana, 2017). Exposure to carcinogens often causes squamous cell cancer and small cell
cancer in the large airways (Piana, 2017). SCLC, which is rare in people who have never
smoked, accounts for approximately 15% of lung cancers and is the most aggressive type
of lung cancer. Patients with SCLC have a 5-year survival rate of 31% with Stage I
SCLC which decreases to a 5-year survival rate of 2% for Stage IV SCLC (ACS, 2018).
Treatment for all types of lung cancer is recommended based on individual patient
characteristics including the type and stage of cancer, as well as concomitant diseases that
affect treatment tolerability, such as underlying pulmonary disease. More recently,
treatment algorithms have been modified due to results of individual genetic testing.
Patients who have never smoked have a higher prevalence of genetic mutations, such as
in the epidermal growth factor receptor (EGFR) gene, or an anaplastic lymphoma kinase
(ALK) gene (Piana, 2017), and respond well to targeted therapy, but are less responsive
to immunotherapy treatments (Piana, 2017).
Treatment recommendations are based on current evidence-based algorithms and
may involve one or more modalities, including surgical resection of the tumor,
chemotherapy, radiation therapy, or biological/targeted therapies (NCCN, 2018). Options
for chemotherapy include anti-neoplastic agents, used either alone or with other agents,
or in combination with radiation therapy. Chemotherapeutic agents commonly prescribed
in the treatment of lung cancer include cisplatin, carboplatin, gemcitabine, pemetrexed,
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paclitaxel, or docetaxel (NCCN, 2018). Biological/targeted therapies include epidermal
growth factor receptor inhibitors, such as afatinib or erlotinib (Hirsch et al., 2017).
After completing a full work up to establish type and stage of cancer, patients
sometimes undergo testing, such as pulmonary function testing, to determine his or her
ability to tolerate treatment (especially for pre-surgical candidates). One or more
modalities of lung cancer treatment may be recommended. After treatment is underway,
treatment response is assessed at specified intervals using radiographical imaging
techniques including computerized axial tomography (CT) or positive emission
tomography/computed tomography (PET/CT). CT scan imaging generates cross-sectional
results that are used to visualize internal organs; the imaging is essential to aid in cancer
diagnosis and to also reassess disease progression (Radiological Society of North
America, 2018). PET/CT, a type of nuclear medicine imaging, utilizes
radiopharmaceuticals to provide images and information to assist in the diagnosis of
cancer and to also mark areas of disease throughout the body, which provides information
to evaluate treatment response (Radiological Society of North America, 2018).
The primary, or optimal, treatment for cancer is often referred to as “first-line,” or
standard therapy. “First-line” is the term used to describe an evidence-based standard
choice of treatment for a particular type of cancer, and has the best likelihood of treating
the cancer successfully. Therapy considered to be “first-line” is contingent on the type
and stage of cancer, and patient-specific considerations, such as results of pulmonary
function testing or genetic testing. Although treatment is not guided by smoking status, it
is individualized based on the type and stage of cancer, and genetic testing, if available.
If, after having received sequential courses of first-line therapy, the patient’s testing does
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not show reduction or stabilization of tumor burden, second-line treatment is often
recommended; if second-line treatment is not successful, third-line treatment may be
recommended (NCCN, 2018; National Cancer Institute, 2015).
A critical oncology outcome yet to be evaluated is whether smoking reduces the
effects of treatment modalities for lung cancer therapy in humans, which would translate
into progression to second-line or third-line therapy (USDHHS, 2014). Progression into
second- and third-line treatment increases treatment duration and may increase the risk of
side effects from medication, adverse effects, and treatment costs. Although the adverse
effects of smoking status on long-term survival outcomes are established, less is known
about the effects of smoking on treatment progression and side effects during treatment
for lung cancer (USDHHS, 2014).
To address the current gap in evidence of whether people who smoke at time of
diagnosis of NSCLC experience poorer short-term outcomes of cancer treatment
compared to their peers who have never smoked or formerly smoked, this exploratory
data analysis was conducted and examined the association between smoking status
(current, former, never smoker) at the time of cancer diagnosis and progression through
first-, second-, and third-line treatments, along with an evaluation of side effects of
treatment in the same patient populations.
Theoretical Framework
The 2014 Surgeon General’s Report (SGR) provided the justification and the
basis for this research study. The dissemination of the 1964 landmark SGR facilitated
considerable progress for transparency and public awareness of the multitude of
tobacco’s health-related effects. Although the harmful effects of tobacco are now widely
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disseminated, there are numerous concerns which inform the need for further research.
Rates of smoking have decreased substantially in the US since the 1964 SGR (from a rate
of 43% in 1965 to 18% in 2014), yet the risk for lung cancer and chronic pulmonary
disease for both men and women who smoke has increased (USDHHS, 2014).
Furthermore, while the 2014 SGR concluded that there is a clear causation between
cigarette smoking and numerous poor health outcomes (including pulmonary disease,
poor circulation, poor wound healing, cancer-specific mortality and all-cause mortality),
evidence has not yet been able to demonstrate a definitive relationship between smoking
and short-term outcomes of response to treatment and treatment toxicity (USDHHS,
2014). Thus, the 2014 SGR is used as a conceptual underpinning and foundation for this
research to begin to explore if there is an association between smoking status and
treatment progression and toxicities and side effects on patients undergoing treatment for
lung cancer. Treatment progression is measured in this manuscript as progression from
first- to second- or third-line treatment, while side effects of treatment for each
participant was recorded. Exploring the association between smoking status at diagnosis
and treatment progression and side effects may help strengthen the growing body of
evidence that supports smoking cessation for individuals undergoing cancer treatment, on
the hypothesis that individuals who do not currently smoke at diagnosis will require less
second-and third-line treatment and may have fewer side effects than their counterparts
who do smoke.
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Methods
Methods used to conduct the retrospective data analysis at the CC are described
below. Characteristics of study design, characteristics, data ascertainment and chart
review form development, as well as independent and dependent variables, follows.
Study Design
The current study employed a retrospective cohort design using a secondary data
analysis. Specifically, a retrospective chart review was conducted to assess the
association between tobacco use status and treatment progression and side effects in adult
patients with lung cancer. Patients who received care at the CC between January 2013
and December 2015 (N= 202) comprised the study population. Prior to chart review and
data collection, the study was approved by the MUSC Institutional Review Board (IRB).
The study compared differences in patient progression through first, second, and
third-line treatment, as well as side effects by patient smoking status (never, former,
current) at the time of their cancer diagnosis.
Participants
Inclusion criteria for the study were: adult patients ages 18 and over with any type
or stage of NSCLC who presented to the CC for treatment between January 1, 2013 and
December 31, 2015 and who received all or most of their lung cancer treatment at the CC
to allow ascertainment of their complete treatment history. The study focused on patients
with NSCLC, the most common lung cancer type that represents a homogenous disease
(ACS, 2018). Response to treatment is measured at specified three- or six-month
intervals; therefore, to allow adequate time after diagnosis to assess treatment response, a
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13-month time frame for treatment progression after the patient’s initial date of diagnosis
of lung cancer was used.
Patients were excluded from the study if they: 1) had been referred to palliative or
hospice care before receiving treatment for lung cancer, 2) were diagnosed with any type
of cancer (except for non-melanoma skin cancer) within the previous five years, or 3) did
not have smoking status recorded in the medical chart.
Data Ascertainment and Eligibility Screening
A roster of medical record numbers (MRNs) of patients (N = 897) evaluated at the
CC for lung cancer during the study time frame was obtained from the MUSC tumor
registrar after IRB approval was received. Records were eliminated for review (n= 395)
in which all or most of the medical care was not provided at CC were not reviewed, as
were duplicate MRNs or MRNs without a primary diagnosis of lung cancer (n=53). The
remaining 502 patient records were sorted by smoking status and reviewed sequentially
for inclusion criteria. Of the 502 records, 131 records were excluded due to one or more
of the following factors: 1) the patient was enrolled in hospice or palliative care after
diagnosis and received comfort-care only treatment (n = 45), 2) the patient had been
diagnosed with any type of cancer (except for non-melanoma skin cancer) within the
previous last 5 years (n=84), or 3) the smoking status was not recorded in the medical
chart (n=2). After inclusion and exclusion criteria were applied, 202 patient records met
criteria for inclusion in the study cohort. Patients whose cases were excluded either
presented to the CC for a consultation only, or received partial treatment from the CC,
but continued treatment at another facility.
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A screening log was used to assess patient data for study inclusion eligibility. If
the patient met inclusion criteria for the study, the process of complete chart review and
collecting data to enter into the database was completed. The screening log was
maintained in REDCap and was antecedent to the REDCap data collection tool.
Chart Review Form Development
Prior to collecting data, we developed a database using REDCap (Research
Electronic Data Capture), an electronic data capture tool hosted at MUSC. REDCap is a
secure, web-based application designed to support data capture for research studies,
providing 1) an intuitive interface for validated data entry, 2) audit trails for tracking data
manipulation and export procedures, 3) automated export procedures for seamless data
downloads to common statistical packages, and 4) procedures for importing data from
external sources (Harris et al., 2009).
Study Measures
Study measures were assessed by identifying pertinent dependent and
independent variables prior to the study. Definitions were operationalized based on the
synthesis of current research and feedback from our thoracic oncologist content expert.
Study measures are delineated below.
Independent Variable: Smoking Status
Smoking status at the time of diagnosis was documented in each patient’s EMR as
"current smoker," "former smoker," or "never smoker" based on self-reported status on
the day of the diagnosis of lung cancer. Smoking status was operationally defined for
each category: (a) current smokers were people who smoked at the time of diagnosis,
whether they quit shortly after diagnosis or continued to smoke; (b) former smokers were
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people who quit smoking at any time up until the day prior to the diagnosis of cancer, and
(c) never smokers were people who had never smoked.
Dependent Variables: Progression, Side Effects and Toxicities
The primary outcome, treatment progression, was determined for each patient.
The operational definition of treatment progression was operationalized as (a) treatment
progression (yes or no), and (b) if treatment progressed, did the patient progress by one
level (first-line to second-line therapy) or two levels (first- to second- and then third-line
chemotherapy). Treatment progression was due to failure of the modality to cure or
stabilize the cancer. Modification of the same type of treatment for any reason, including
allergy, was not considered treatment progression.
Data reflecting treatment progression were obtained by reviewing physician
documentation in the chart which indicated if the patient did not respond to first-line
treatment (either chemotherapy with or without radiation, radiation alone, surgery, or
biological/targeted therapy), the patient would require second-line or third-line treatment
of any modality. If the patient received second- or third-line treatment, that was counted
as treatment progression. Dates of first therapy, last therapy, date of entry into palliative
care, hospice, or death (and whether the patient died in the study time frame) were
recorded.
Side effects from treatment were quantified using input from our thoracic
oncologist content expert. Treatment for cancer is designed to eradicate cancer cells, but
often has the potential to destroy healthy cells and induce side effects or toxicity.
Common side effects include nausea, vomiting, weight loss, hair loss, fatigue, mucositis,
as well as more system-wide effects of suppressed blood counts, including anemia,
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neutropenia, and pancytopenia (Plenderleith, 1990)). We confined the operational
definition of side effects to include any side effects that led to delay in treatment,
cessation of treatment, or hospitalization. Side effects included in the REDCap data
collection tool were: neutropenia, anemia, pancytopenia, neuropathy, edema, sepsis,
significant pulmonary function change, deep venous thrombosis, cardiac side effects,
dehydration, dysphagia, odontophagia or weight loss. A free text “other” option for any
other side effect that impacted treatment, such as decreased liver function, was also
included. Side effects were not weighted by severity.
Covariates
Covariates were type and stage of cancer, age in years, alcohol use (used any
alcohol or did not ever use alcohol), gender (male or female), ethnicity (White, Black,
Asian, Hispanic, or other), marital status (single, married, separated, divorced, widowed,
living with partner) insurance status (type of insurance). Concomitant disease processes
were extracting salient patient comorbidities and then calculating a score for each patient
using the Charlson comorbidity index (CACI) (Charlson, Szatrowski, Peterson, & Gold,
1994). The CACI is a reliable and valid method of assessing a risk ratio (RR) using
weighted patient comorbidities based on the International Classification of Diseases
(ICD) data. The multidimensional CACI yields a projection of overall risk for mortality
in populations with comorbidities that may affect prognosis, as well as overall costs of
chronic diseases (Charlson, Wells, Ullman, King, & Shmukler, 2014). One point is
assigned to a patient at each decade of life starting at the age of 50. Further weighted
points are accrued for concomitant diseases such as metastatic or non-metastatic tumors,
diabetes with or without target organ damage, renal disease, connective tissue disease,
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mild or moderate hepatic disease, chronic pulmonary disease, myocardial infarction,
congestive heart failure, or dementia. The CACI score provides a validated, quantitative
measure of RR. The lowest score possible for an individual with any type of solid
malignant tumor is 2; the highest CACI score theoretically possible on the scale is 38. A
copy of the study instrument of the CACI scale used can be found online at
http://www.pmidcalc.org/?sid=7722560&newtest=Y.
Chart Review Process
The projected initial sample size was 309 participants, or 103 patients in each of
the 3 smoking status categories (current, former and never smokers). After medial record
review was complete and the data were entered, each of the records were reviewed for
completeness and accuracy, while comparing the chart data to the REDCap database
before exporting data from REDCap into SPSS statistical software, version 24, for
analysis.
Second Investigator Consultation
During ongoing review of the charts, the PI recorded clinical questions that arose
during data collection and noted the questions on a secure database with the MRNs. Our
consultant radiation oncologist answered clinical questions for approximately 20%
(n=40) of the charts undergoing review and provided regular feedback on operational
definitions for each of the study variables and final outcome measures.
Statistical Analysis
Data analyses were conducted with the Statistical Program for the Social Sciences
(SPSS version 24.0). The following steps were undertaken complete the statistical
analyses in the sequential order listed below.
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Missing data
The first step of analysis was to visually inspect the dataset for missingness. After
visual inspection was completed, a REDCap analysis feature was enlisted to determine
the presence or absence of unexpected missing values. If missing data values were noted
in the dataset, the PI reviewed each individual chart and then addressed each instance to
ensure completeness and accuracy of the database.
Descriptive statistics
Next, descriptive data were calculated to describe the population characteristics.
Variables were aggregated as needed for analysis. For example, there were initially seven
categories of marital status in the database (single, married, separated, widowed,
divorced, living with a partner, unknown) that were combined to “married” or “not
married” after the initial demographics were reported.
To determine which predictor variables (for example, stage of cancer, marital
status, gender, ethnicity and health insurance status) were associated with progression
through first-line, second-line and third-line cancer treatment (referred to as “treatment
progression”), a multi-step process was utilized. First, demographic variables were
evaluated and identified as potential predictor variables of treatment progression.
Treatment progression was operationalized both dichotomously (no treatment progression
or treatment progression), and also on an ordinal basis, as treatment progression by one
level or two levels. Predictor variables were assessed for inclusion in the logistic
regression model with the chi-square test of association using a p-value of 0.2 or less.
Although a p-value of up to 0.2 is not considered statistically significant, lowering the
p-value to 0.05 for purposes of including predictor variable values can lead to the
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inadvertent exclusion of salient predictor variables in the logistic regression model
(Bursac, 2008).
Three predictor variables, stage of cancer, marital status and health insurance
status were included in the logistic regression model due to the presence of a Chi-square
test of association or Fisher’s exact test using a cut off value of p ≤0.2.
Relationship of progression and smoking status (current vs former vs never smokers)
After predictor variables were identified for inclusion in the model, a logistic
regression analysis was conducted to determine if the probability of treatment
progression could be predicted by smoking status. Hypothesizing that current smoking
would adversely affect cancer treatment progression, the logistic regression model
included the predictor variables stage of cancer, health insurance and marital status.
Relationship of progression and smoking status (current vs former smokers)
Since there were significantly fewer never smokers in the sample (n=26), the
logistic regression was repeated including only current and former smokers, using current
smokers as the referent population. The final model included a logistic regression model
with predictor variables of stage of cancer, marital status and health insurance to
determine if smoking status (current, former and never smokers, and then including only
current and former smokers) affected treatment progression.
Side effects
A Chi-square test of independence was conducted to determine if an association
existed between smoking status and pertinent treatment side effects, coded as yes or no.
Side effects did not include a weighted score, but were included if they caused a delay in
treatment, or cessation of treatment, or hospitalization of the patient. Side effects were:
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neutropenia, anemia, pancytopenia, neuropathy, edema, sepsis, significant pulmonary
function change, deep venous thrombosis, cardiac side effects, dehydration, dysphagia,
odontophagia, weight loss, or other.
Death during study
Patient death during the study, from any cause, was recorded dichotomously as
yes or no. A Chi-square test of association was conducted to see if death during the study
from any cause was associated with smoking status.
Results.
Demographics
Table 1 presents the demographic characteristics of the 202 patients included in
the retrospective analysis. The study cohort consisted of 84 current smokers, 92 former
smokers, and 26 individuals who had never smoked at the time of diagnosis of NSCLC.
The overall cohort (n=202) was 67.2 years (SD = 9.6), with age ranging from 37 to 88
years. The group of current smokers had the youngest median age of 63 years (SD 9.1),
while the individuals who had never smoked had the oldest median age (72 years, SD
11.8). Slightly over half (52.5%, n=106) of the cohort was female, nearly three-quarters
of the participants (68.8%, n=139) were White, and slightly over half of the participants
(53.5%, n=108) were married. Over half of the participants (54%, n=109) had stage I/II
cancer at diagnosis, while 16% had stage III cancer (n=34). Almost three-quarters
(72.6%, n=138) of the sample had adenocarcinoma. Of the 26 people who never smoked
in the study, almost all (96%, n=25) had adenocarcinoma, which is consistent with
literature that indicates most never smokers are diagnosed with adenocarcinomic
histology (Piana, 2017).
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Predictor variables
Table 2 details the Chi-square results between potential predictor variables and
treatment progression. Predictor variables of treatment progression included stage of
cancer (Fisher’s exact test p = .001), marital status (χ2 (1) = 4.1, p = .04) and health
insurance status (Fisher’s exact test p = .001) and were included in the logistic regression
model.
Table 3 illustrates the participants who progressed in treatment by smoking status.
Of the 202 participants, only 9% (n=20) of experienced treatment progression in the
13-month time frame (19 patients progressed from any modality of first-line to
second-line therapy, while 1 patient progressed from second-line therapy to third-line
therapy which was in this case, radiotherapy). Of those patients that progressed to any
modality of second- or third-line therapy, 5 were current smokers, 9 were former
smokers, and 6 were never smokers.
The logistic regression model, the results of which are listed in Table 4, shows
that former smokers had 5.7 times the odds being in the no treatment progression group
when compared to the reference group of never smokers (p=.02). Current smokers had
2.5 times the odds of being in the no treatment progression category than never smokers,
although that result did not approach statistical significance (p=.18). When the model was
repeated using only current and former smokers , the former smokers had 2.1 times the
odds of being in the no progression category of the current smokers, although again, the
results did not reach statistical significance (p=.24).
Side effects by treatment status, described in Table 5, did not show a statistically
significant association between smoking status and side effects that interrupted or
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delayed treatment for cancer (χ2 (2), = 2.9, p = .23), nor did smoking status predict the
number of side effects in this study (F (1, 231) = 1.95, p=.16; R2 .008).
Death during study
Table 6 shows patient death from any cause during the course of the study.
While 27% (n=23) of the current smokers and 30% (n=28) of the former smokers died
within the study, only 8% (n=2) of the never smokers died from any cause during the
study, although the results did not reach statistical significance (χ2 (2), = 5.5, p = .06).
Discussion
To our knowledge, this research study is one of the first to explore the association
between smoking status and treatment response as defined by progression of first-line,
second-line and third-line treatment in patients with lung cancer. We hypothesized that
current smokers would progress more frequently through first-, second-, and third-line
cancer treatment as compared to former/never smokers, and experience fewer treatmentlimiting side effects when compared to former/never smokers. However, our results
indicated that the former smokers experienced 5.7 times the odds of being in the “no
treatment progression” group when compared to the referent group of never smokers ,
(p=.02). Additionally, current smokers in this study had 2.5 times the odds of not being in
the “no treatment progression” group than never smokers (OR 2.5, p =.18). Although the
latter result did not reach statistical significance, these findings raise several questions
worth considering. Intuitively, the assumption that the referent group of never smokers
with lung cancer fare well during their treatment and experience remission after first-line
treatment is reasonable, but in this study, never having smoked did not confer positive
effects in terms of less treatment progression.
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There are several theories that may explain these counterintuitive findings. The
first important consideration is that the operational definition of “treatment progression”
is different than the concept of “disease progression”. Patients may have experienced
disease progression, but not elected to undergo further treatment progression. One
example would be of a current smoker who experienced progression of disease, but was
too medically frail to continue treatment, or who saw further treatment as futile. Another
point for consideration is that former smokers, by the virtue of having quit smoking, often
seek out services earlier than current and never smokers for lung cancer symptoms and
may be diagnosed at an earlier stage, and be motivated to continue to pursue treatment
(Dias, Linhas, Campainha, Conde, & Barroso, 2017; Friedemann Smith, Whitaker,
Winstanley, & Wardle, 2016). Although our sample population had a relatively equal
representation of patients with each stage of cancer (see Table 1), it is not possible to
control for all other variables, and it should be considered that some patients in each
group could have been less or more acutely ill, thus affecting their treatment decisions.
Although our study aims did not set out to examine long term effects of all-cause
mortality in our population, it is notable that less patients that never smoked (8%) died
during the study time frame than current smokers (27%) and former smokers (30%), (χ2
(2), = 5.5, p = .06), so it is possible that never smokers experienced more treatment
progression but did not die during the study as members of the former and current
smoking groups.
Never smokers with lung cancer are often considered to have different pathology
with a different disease trajectory (Planchard & Besse, 2015). For example, Stiles et al.
(2018) conducted a retrospective review of patients with cancer who were undergoing
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surgery (N=232), and reviewed disease survival rates and cancer specific survival in
patients undergoing surgery). When outcomes of patients who never smoked (n=718)
were compared with outcomes of current smokers (n=2514), no effect was observed in
the univariate analysis either 5-year disease free survival or cancer-specific survival
(Stiles et al., 2018). While the Stiles (2018) study looked at survival in never smokers
versus the more proximal effects as noted in our study, this observation still lends
credence to the emerging knowledge that patients who have never smoked do not always
fare better in lung cancer treatment in terms of less disease progression, theorized to be
due to a unique type of disease and treatment trajectory (Piana, 2017).
Due to the relatively low sample size (n=26) of never smokers, we repeated the
logistic regression model using only current and former smokers to ensure that our results
were relatively consistent with the previous model. When current smokers were used as
the referent group, former smokers had 2.1 times the odds of being in the “no treatment
progression” group, although the results did not reach statistical significance (p=.24).
Although the findings of former smokers being less likely of being in the “no treatment
progression group” as compared to current smokers were limited due to lack of statistical
power, these findings support guidelines published by key organizations (NCCN, 2018),
encouraging more current smokers to quit smoking and join the “former smoker”
category, especially before or during lung cancer treatment.
We also reviewed side effects from treatment and postulated that current or
former smokers would have more adverse effects than never smokers. Although smokers
who undergo lung cancer treatment are known to have more side effects such as
mucositis, research to date to date has indicated an association, but not causation, of
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treatment-related side effects and toxicities due to smoking (USDHHS, 2014). We
operationalized our definition of side effects/treatment toxicities to any effect that caused
a delay, interruption, or cessation of treatment. However, in this study, there was also not
a significant effect of treatment side effects by smoking status. Previous studies have also
shown mixed results. Peppone et al. (2011), in a previous study of 947 cancer patients
reported increased symptoms in smokers compared to non-smokers (smokers = 46.3
versus non=smokers = 41.2; p < 0.05 during treatment for cancer and at follow up, but
other studies (Szeszko et al., 2015) in cancer patients (N=136) with mucositis found no
statistically significant side effect results when individuals who continued to smoke
underwent radiation treatment. Again, we were limited in our comprehensive
understanding of side effects. If a side effect caused cessation of treatment and then the
patient subsequently resumed treatment, it was counted the same way as if the patient had
a side effect that caused cessation of treatment completely. If treatment was delayed by a
month due to persistent neutropenia, the side effect was counted in the same manner in
which someone with intractable vomiting and dehydration had to stop treatment
completely. There was no weight for side effect severity assigned.
Although not statistically significant, in this study, former smokers were more
likely to be in the “no treatment progression” category compared to current smokers, a
concept which reinforces current research indicating that it is imperative for centers to
provide tobacco cessation services for patients who need them. There may be several
types of barriers impinging on patients receiving the care they need. Health care
providers may doubt the necessity of recommending tobacco cessation services to
patients with cancer. Patients with cancer also face barriers to tobacco cessation services;
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including lack of self-efficacy or a perception that tobacco cessation would have an
impact on the overall treatment plan. Thus, the current research study was designed to
explore the association between tobacco use at time of lung cancer diagnosis and the
effects of current tobacco use on treatment progression. Regardless of the limitations of
this small study, we still maintain that NCCN’s (2017) guidelines urging health care
providers to assess smoking status at every visit, and recommend smoking cessation to
patients, including those who are undergoing treatment for cancer, are necessary and
provide a key component of medical care for patients with cancer.
Limitations
Several limitations to the study should be considered. Although a retrospective
data analysis of electronic medical records is often utilized to provide an opportunity for
data collection, there are disadvantages to analysis of secondary data. Demographic data
available may be limited and not fully represent the general population; these data were
collected from a single academic medical center with one reviewer abstracting all
appropriate data points in each of the 202 charts. We used secondary data, and so we
were limited to data that were available in the electronic health record.
The relatively small sample size also limited the study; although the sampling
plan was intended to have 103 patients each of current, former, and never smoking
categories to ensure adequate power, there were only 26 patients who had never smoked
who had lung cancer and met inclusion criteria in the time frame from January 1, 2013
and December 31, 2015, which was most likely the most profound limitation of this
study. Due to a small sample size, results from these 26 patients who had never smoked
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may not have been truly representative of the larger never-smoking population with lung
cancer.
Also, smoking status was based on self-report and not verified by cotinine
analysis, which may limit smoking status accuracy. There may have been smokers in the
“former” category who were actually “current” smokers. Additionally, among the
participants noted as “former” smokers, the quit date was not recorded. Thus, a former
smoker could have quit 20 years ago or the day before the diagnosis of lung cancer,
which could have affected results. Several patients quit smoking during their treatment
for lung cancer, which may have affected their prognosis. “Pack years”, or the packs the
patient smoked per day multiplied by the number of years the patient smoked, may have
been a factor also. Alcohol use was also collected, but the amounts were unreliably noted
in the documentation (perhaps due to the high rate of recidivism in heavy alcohol users or
to stigma which affected self-reporting); thus, the alcohol use variable was reduced to a
dichotomous answer of yes or no and did not include amounts of alcohol consumed.
The relatively high survival rate of patients with NSCLC, although fortunate for
the patient, should also be considered as a limitation of this study that followed a cohort
for a 13-month time period. Given the fact that over half of our study population had
stage I/II NSCLC, and the 5-year survival rate for people with stage IA NSCLC is
approximately 92%, progression of treatment would be best assessed using a longer
follow-up period of three to five years, rather than the 13-month time follow-up period
that was utilized for this study.
Another important limitation was that although “treatment progression” was
operationalized as progression from first-line to second-and third-line therapy, our
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operationalized definition of treatment progression may have overlapped with true
disease progression. For example, if a patient did not progress from first- to second-or
third-line treatment but had disease progression and elected to stop treatment or was too
frail to continue further treatment, the results would differ from those of a relatively
healthy patient who was able to endure multiple treatment progressions with the hope of
remission or cure. Thus, the operational definition of treatment progression was limited.
In this study, the PI reviewed only “treatment progression” but not “disease progression”,
which are subtle distinctions but may yield different endpoint results. We also did not
study palliative care or hospice patients due to the accelerated disease trajectory and
alteration of what is considered first-line versus comfort treatment in those populations. It
would be interesting to know if smoking in palliative care and hospice populations
affected further treatment progression or side effects.
Conclusions
This was a small study with several limitations. However, it was the first study, to
our knowledge, to begin to evaluate treatment progression in current, former and never
smokers. After conducting this study, we have identified several ways in which future
research in this area could be strengthened. First, it would be helpful to add a qualitative
approach to be able to interview a small population of the patients undergoing treatment
about their perceptions and/or barriers pertaining to smoking cessation. For example,
never smokers, when faced with a diagnosis that exists primarily in smokers, may feel
stigmatized into a disease in which patients who smoke feel judged. Smokers may be
reluctant to report relapses in tobacco use, and may report being former smokers. With
regards to treatment progression, it would be better suited to integrate “treatment
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progression” and “disease progression” so that the outcomes can be best measured more
effectively. Further studies would most likely show more data points available for follow
up of outcome assessment if the patients were studied for a longer time frame; for
example, three to five years. Despite the small number of patients, this study provides an
exploration of a small protocol that can be built upon in order to conduct a larger study
with a larger sample population utilizing a longer time period for outcome assessment.
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Table 1. Demographic Features of Sample by Age and Smoking Status
Characteristic
Age (median, SD)
Race
White
Black
Asian
Other

Current Smoker
(n = 84)

Former Smoker
(n = 92)

Never Smoker
(n = 26)

p value

63 (9.1)

69 (8.5)

72 (11.8)

-

63.1%
36.9
0
0

73.9%
20.7
3.3
2.2

69.2%
23.1
0
7.7

.302a,b

.006a

Gender
Male
Female
Marital Status
Single
Separated
Divorced
Widowed
Married
Unknown

54.8
45.2

48.9
51.1

19.2
80.8

23.8
7.1
20.2
10.7
36.9
1.2

9.8
5.4
6.5
9.8
68.5
0

11.5
0
0
26.9
53.8
7.7

Cancer Stage (NSCLC)
I/II
III
IV
Unknown

51.2
21.4
26.2
1.2

57.6
12.0
29.3
1.1

50.0
19.2
26.9
3.8

.00a, c

.567a d

.002a
Cancer Type
Adenocarcinoma
Squamous Cell

62.0
38.0

75.3
11.1

96.2
3.8

Charlson Category
2-9
10-17

57.1
42.9

48.9
51.1

69.2
30.8

Alcohol Use
Yes
No
Unknown

45.2
51.2
3.6

39.1
56.5
4.3

23.1
73.1
3.8

Type of Health
Insurance
Governmentb
Commercial
No Insurance

.16a

0.12a,c

.23a,c
73.8
14.3
11.9

82.6
10.9
6.5

80.8
19.2
0
.002a

Cancer Type
Adenocarcinoma
Squamous Cell
Charlson Category
2-9
10-17
Alcohol Use
Yes
No
Unknown
Type of Health
Insurance
Governmentd
Commercial
No Insurance

62.0
38.0

75.3
11.1

96.2
3.8

57.1
42.9

48.9
51.1

69.2
30.8

45.2
51.2
3.6

39.1
56.5
4.3

23.1
73.1
3.8

.16a

0.12a,c

.23a,c
73.8
14.3
11.9

82.6
10.9
6.5

80.8
19.2
0

Data are represented as mean ± SD for continuous variables and percentage for categorical variables
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a p value was calculated using Chi-square test
b p value was calculated using only White and non-White categories
c p value was calculated using only 2 categories used in analysis due to small sample size: Married vs. Not married
d p values reported after deleting 3 unknown cases where stage was not known

Table 2. Smoking Status and Potential Predictor Variables
Treatment progression
(n=20), %

No treatment progression
(n=182), %

.028a

Smoking status
Current Smoker
Former smoker
Never smoker

9 (45%)
5 (25%)
6 (30%)

75 (41.2%)
87 (47.8%)
20 (11%)
.90a

Race
White
Non-White

14 (70%)
6 (30%)

125 (68.7%)
57 (31.3%)
.31b

Gender
Male
Female

8 (40%)
12 (60%)

88 (48.4%)
94 (51.6%)

Marital Status
Married
Not married

χ2

.04 a
15 (75%)
5 (25%)

93 (51.1%)
89 (48.9%)
.001 b, c

Cancer Stage (NSCLC)
I/II
III
IV

4 (20%)
8 (40%)
8 (40%)

105 (58.7%)
26 (14.5%)
48 (26.8%)

Cancer Type
Adenocarcinoma
Squamous Cell

14 (77.8%)
4 (22.2%)

124 (72.1%)
48 (27.9%)

Charlson Category
2-9
10-17

10 (50%)
10 (50%)

101 (55.5)
81 (44.5%)

Health Insurance Status
Government
Commercial
None

10 (50%)
8 (40%)
2 (10%)

149 (81.9%)
19 (10.4%)
14 (7.7%)

8 (42.1%)
11 (57.9%)

72 (41.1%)
103 (58.9%)

Alcohol Use
Yes
No

.420b

.645b

.001b

.56b

Table 3. Smoking Status and Progression of Treatment
Treatment Progression

Progressed in treatment
Yes
No

Current Smoker
(n = 84)

Former Smoker
(n = 92)

Never Smoker
(n = 26)

9 10%)
75 (89%)

5 (5%)
87 (95%)

6 (23%)
20 (77%)
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Table 4. Logistic Regression Analysis for No Treatment Progression in All Groups of
Smoking Statuses

Predictor
Marital Status
Not married
Married

95% CI, Odds Ratio
Lower
Upper

Odds Ratio

p-value

3.2

.953

11.53

.06

Stage
I/II
III
IV

2.4
.38
-

.621
.109

9.8
1.3

.19
.14
.20

Health Insurance
Govt Funded
Commercial/Private
None

2.8
.73
-

.466
.109
-

17.2
4.9
-

.25
.75
.07

Tobacco Use Status
Never
Former
Current

5.7
2.5

1.35
.647

24.4
9.8

.05
.01
.18

Constant

.96

-

-

.97

Table 5. Smoking Status and Side Effects
Characteristic

Current
Smoker
(n = 84)

Former Smoker
(n = 92)

Never Smoker
(n = 26)

χ2

.61
Side Effects
Yes
No

32 (45.1%)
52 (61.9%)

29 (31.5%)
63 (68.5%)

10 (38.5%)
16 (61.5%)

Table 6. Participants Who Died from Any Cause During 13-month Study Time Frame
Current
Smoker
(n = 84)

Former Smoker
(n = 92)

Never Smoker
(n = 26)

χ2

.06
Died During Study
Yes
No

24 (28.5%)
60 (71.4%)

28 (30.4%)
63 (68.5%)

2 (7.7%)
24 (92.3%)
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PRELIMINARY REPORT OF COST

Manuscript 3
Preliminary Report of Cost of Second-and Third-Line Chemotherapy in a Retrospective
Data Analysis of Patients with Lung Cancer
Abstract
BACKGROUND: Health care spending increased in the United States between 1990 and
2008, with one estimate estimating that cost tripled from $27 billion in 1990 to over $90
billion in 2008. In an effort to contain cost and provide state of the art care in the largely
preventable diseases caused by smoking, this manuscript reports cost based on Average
Wholesale Price (AWP) for patients receiving first-, second- and third-line
chemotherapy. We did not include costs for administration fees, physician charges,
outpatient administration fees, or costs for patients that underwent surgery or radiation.
METHODS: Specific chemotherapy treatment was identified through retrospective data
review, and costs of individual chemotherapy treatments were calculated based on the
Average Wholesale Price (AWP). We compared means of chemotherapy costs among
never, former, and current smokers.
FINDINGS: Of the 202 patients in the study, 72 received first-line chemotherapy, and 13
progressed from first-line to second-line chemotherapy. None of the patients progressed
from second-line to third-line chemotherapy. When reviewing second-line treatment,
patients who formerly smoked (n=35) had the lowest mean cost of second-line treatment,
with a mean of $31.56. The patients who currently smoked (n=29) had a cost average of
$1805.24. The patients who never smoked (n=8) had the highest cost regimen averaging
$5,705.26 per patient.
CONCLUSION: There are several theories for the counterintuitive findings that never
smokers had higher chemotherapy costs, including the use of newer targeted therapies for
never smokers. Current smokers may also have been too medically frail to undergo
multiple therapies, thereby reducing the cost of further treatment. Further research is
needed to further capture the true cost of treatment across the groups of current, former
and never smokers.
KEYWORDS: Lung Cancer, Cost, Treatment Progression, Second-Line Treatment
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Introduction
Lung cancer is the second most common type of cancer for both men and women
in the United States (US), and is also the leading cause of death from cancer (American
Cancer Society [ACS], 2018b). Approximately 234,030 new cases of lung cancer will be
diagnosed in 2018, resulting in an estimated 154,050 deaths (ACS, 2018). Cigarette
smoking is the primary contributing factor in approximately 80-90% of cases, although
non-smokers are also diagnosed with lung cancer (Malhotra et al., 2016; United States
Department of Health and Human Services [USDHHS], 2014). Tobacco use is linked to
over 12 types of cancer, as well as cardiovascular disease and chronic lung disease
(USDHHS, 2014). In addition to the cost of lives from tobacco-related diseases,
tobacco-related morbidity and mortality places a financial burden on an already strained
healthcare system. Over $150 billion, more than half the approximate total economic cost
of smoking every year, is attributable to the direct medical care of adults in the US
population (CDC, 2018).
Medical costs have increased significantly for individuals diagnosed with all types
of cancer. Between 1990 and 2009, one estimate indicates that annual medical spending
for direct costs of all type of cancer more than doubled in the US, from approximately
$27 billion in 1990 to over $90 billion in 2008 (Elkin & Bach, 2010). Recent data
published by the American Cancer Society (2018) indicates that employers, insurance
companies, public programs and individuals in the US spent over $87 billion on
cancer-related health care by (ACS, 2018). Patient out-of-pocket costs toward insurance
premiums, deductibles, and co-payments represented $3.9 billion of the overall amount of
health care spending by employers in 2014 (ACS, 2018). Prescription medications have

PRELIMINARY REPORT OF COST

98

also increased in cost. Retail prescription medicine expenditures for cancer-related
medications increased fivefold from 2001 to 2011, from $2 billion in 2001 to $10 billion
in 2011 (Agency for Healthcare Research and Quality [AHRQ], 2014). Although current
US legislation requires most private insurance plans to limit out-of-pocket spending for
patients, the upper deductible limit in 2017 was $7,150 for an individual plan (ACS,
2018). Even if patients and families have insurance, they are too often faced with a
substantial financial burden in treating cancer.
Lung Cancer Treatment
Lung cancer is treated using several modalities, including chemotherapy, surgery,
and radiation (NCCN, 2018). Clinically, treatment is individualized by the oncologist or
surgeon using evidence-based guidelines that refer to “line” of treatment, while tailoring
the treatment plan specifically to each patient. “First-line” treatment is a term used to
describe the optimal treatment for the stage, type, and histology of cancer, and is the most
likely to induce remission or cure (ACS, 2018). If the patient does not respond to firstline treatment as evidenced by reduced or stabilized tumor burden using serial follow-up
CT scans, then second-line or third-line treatment may be recommended (NCCN, 2018;
National Cancer Institute, 2015).
People who undergo treatment for lung cancer receive services on an inpatient or
outpatient basis, and are treated with first-line chemotherapy, radiation or surgery which
is contingent upon the type and stage of cancer (ACS, 2018). Cancer treatment costs are
charged based on modality and setting. For example, intravenous (IV) medications are
often covered under an insurance plan’s medical benefit and are accompanied by
medication administration costs, while oral (PO) medications are often covered under the
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plan’s pharmacy benefit, resulting in separate deductibles charged to the patient (ACS,
2018). For individuals who are uninsured, the financial burden may be even more
substantial due to delayed access to treatment and financial difficulties (ACS, 2018).
Cost of Chemotherapy and Smoking Status
While patients undergoing treatment for lung cancer begin with first-line therapy,
if cure or remission is not achieved, second- and third- line therapy may be
recommended. However, continued courses of treatment are contingent on the patient’s
willingness and ability to undergo additional therapy. We theorize that patients who are
current smokers may require additional second-line treatments and thus incur higher
additional second-line chemotherapy costs as compared to former smokers.
For never smokers, emerging research indicates genetic mutations, such as
mutations in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma
kinase (ALK) genes, are present at a higher prevalence (Ou, Bartlett, Mino-Kenudson,
Cui, & Iafrate, 2012). “Targeted” therapy, or therapy prescribed based on known genetic
mutations, may improve patient outcomes, at least in terms of survivability (Donner et
al., 2018; Schuette et al., 2015). While “precision medicine” for cancer has shown a
favorable response for increased survival (Passaro et al., 2016; Schuette et al., 2015),
newer, targeted therapies may result in higher costs (Schuette et al., 2015). Thus,
although there are known contributing factors that affect treatment costs for lung cancer,
the aim of the present study was to compare chemotherapy costs of second-line and
third-line treatments in for patients with non-small cell chemotherapy across smoking
statuses.
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Theoretical Framework
The 2014 Surgeon General’s Report (SGR) provided the justification and the
basis for this research study. The rates of smoking have decreased substantially in the US
since the 1964 SGR (from a rate of 43% in 1965 to 18% in 2014), but the risk for lung
cancer for both men and women who smoke has increased (USDHHS, 2014). In view of
increasing healthcare-related costs dedicated to treating a highly preventable disease
(CDC, 2018), results of this preliminary cost report in patients undergoing second-and
third-line chemotherapy may help demonstrate that tobacco cessation services are worthy
of time, resources, and financial investment in terms of cost savings. As the 2014 SGR
introduction reminds readers, “with intense use of proven interventions, we can save lives
and reduce health care costs” (SGR, 2014, p i).
Methods
A retrospective, exploratory design was used to accomplish the aim of this study.
Electronic medical record (EMR) data were obtained from a review of charts of a cohort
of patients (N=202) who were diagnosed with non-small cell lung cancer (NSCLC) at a
southeastern university-affiliated Cancer Center (CC) between January 2013 and
December 2015. The study was approved by the MUSC Institutional Review Board
(IRB) prior to collecting data. The Principal Investigator (PI) reviewed charts to record
demographic variables pertaining to the patients, and then identified the patients who
received chemotherapy. Chemotherapy costs of first-line, second-line, and third-line
agents were calculated and based on Average Wholesale Price (AWP) of participants
who received chemotherapy and segmented according to the line of treatment.
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Participants
To be included in this retrospective analysis, individuals were required to be ages
18 and over and to have received a diagnosis of NSCLC between January 1, 2013 and
December 31, 2015. Patients were excluded from the study if they: 1) had been referred
to palliative or hospice care before receiving treatment for lung cancer, 2) were diagnosed
with any type of cancer (except for non-melanoma skin cancer) within the previous last 5
years, 3) did not have smoking status recorded in the medical chart, or 4) did not receive
all/most of their care at this CC.
Study Measures
Study measures were assessed by identifying pertinent dependent and
independent variables prior to the study. This study was designed to illustrate the cost of
additional second-line chemotherapy, regardless of the method of delivery (intravenous
[IV] or oral [PO] medications. To report preliminary costs of chemotherapy, we used the
AWP, which reflects the average price for medications purchased by pharmacies and
hospitals on a wholesale level. The AWP is self-reported by manufacturers and may not
reflect prices actually paid by the hospital or insurance company. We did not obtain
infusion or administration costs, but used the AWP as a relative comparison tool for
medication cost data (Alpert, 2013).
Independent Variable: Smoking Status and Treatment Line
Smoking status at the time of diagnosis was documented in each patient’s EMR as
"current smoker," "former smoker," or "never smoker" based on self-reported status on
the day of the diagnosis of lung cancer. Smoking status was operationally defined for
each category: (a) current smokers were people who smoked at the time of diagnosis,
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whether they quit shortly after diagnosis or continued to smoke; (b) former smokers were
people who quit smoking at any time up until the day prior to the diagnosis of cancer, and
(c) never smokers were people who had never smoked.
Treatment line was first-line, second-line, or third-line treatment, noted by the
oncologist or thoracic surgeon in the patient’s EMR. Medications and dosages were
extracted from the EMR.
Dependent Variables: Chemotherapy Cost and Line of Treatment
The primary outcome, cost of chemotherapy, was determined for each patient
who received chemotherapy. The operational definition of chemotherapy cost was
determined based on the AWP of the chemotherapeutic agent, which was then multiplied
by the number of cycles of each agent that the patient received. Line of treatment was
extracted from the patient’s EMR.
Measurement of Chemotherapy Cost
Standard prices for each medication were obtained from the published AWP of
each medication, which is used as one measure of pricing and reimbursement for
government and private payers. Our consultant pharmacist provided feedback on the
medication costs based on how the chemotherapy was dispensed. For example, a patient
receiving 500 mg of carboplatin IV would require that a 600 mg vial be opened in order
to dispense the medication properly, and the additional medication would have to be
discarded. The cost of the medication based on the appropriate unit dosing for each
patient was hand calculated and then verified by our pharmacist consultant.

PRELIMINARY REPORT OF COST

103

Statistical Analysis
Data analyses were conducted with the Statistical Program for the Social Sciences
(SPSS version 24.0). The overall cost of chemotherapy was tabulated and compared
between patients by smoking status and segmented by first-, second-, or third-line
chemotherapy.
Results
Participant Characteristics
Table 1 displays a summary of participant demographic characteristics. Of the
202 patients in the study, 36% (n=72) received first-line chemotherapy for treatment of
NSCLC. Of the patients (n=72) receiving chemotherapy, 6% (n=13) progressed to
second-line chemotherapy due to first-line treatment failure, while no patients progressed
from second- to third-line chemotherapy. Table 2 provides demographics for the patients
that progressed to second-line chemotherapy. As highlighted in Table 2, 5 of the patients
that progressed to second-line treatment were current smokers, 1 patient was a former
smoker, and 7 patients were never smokers.
Average Cost of First-Line Chemotherapy
Table 3 highlights the costs for patients undergoing chemotherapy, averaged by
group. The cost of care for chemotherapy for each participant was delineated by smoking
status and which chemotherapeutic agent the participant received. Patients who were
former smokers had the highest average of first-line care; the mean cost was $8,711,
followed by current smokers ($7,251). Never smokers had the highest cost of first-line
treatment, with an average of $12,892.
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Second-line Chemotherapeutic Agents
Table 4 illustrates the specific second-line agents used and the cost associated in
each of the 13 patients that received second-line chemotherapy. Targeted agents,
nivolumab and crizotinib, were administered to three patients and were among the
highest priced chemotherapeutic agents.
Discussion
In this preliminary cost report of second-line chemotherapy in a small (n=13)
cohort of patients that received second-line chemotherapy, former smokers incurred the
lowest average cost for second-line chemotherapy ($31.56), followed by current smokers
($1,805.24) and never smokers ($5705.26). Given the higher medical costs of newer,
targeted therapies used primarily in never smokers (Schuette et al., 2015), the high cost in
never smokers was not an unexpected finding. However, the lower cost of second-line
chemotherapy for former smokers in this study could be misleading. Initially, lower costs
for former smokers could be interpreted as an indication that former smokers experience
remission disease sooner than current smokers, although it remains unclear as to whether
former smokers experienced disease remission earlier or required less treatment due to
increased mortality. If taken at face value, the lower second-line chemotherapy costs for
former smokers emphasizes the current evidence that providing smoking cessation to
smokers, even those undergoing cancer treatment, is necessary and cost effective.
Providing tobacco cessation services, although congruent with evidence-based
practice, raises concerns about how to best deliver cost-effective care. Several key
organizations have recognized the need to provide tobacco cessation services to patients
with cancer. The Patient Protection and Affordable Care Act (ACA) now requires
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tobacco cessation services to be integrated into preventive services with no patient cost
share for all FDA-approved medications (Lemaire, 2015). In an effort to address potential
concerns from administrators and providers about costs of program implementation,
Baker, Ferrufino, Bruno, and Kowal (2017) provided an innovative study that estimated
the cost impact of implementing ACA-required smoking cessation coverage on
healthcare plan budgets. In a Markov cost analysis designed to estimate the cost of
tobacco cessation services would cost, the cost per-member per-month (PMPM) for
smoking medications was projected to be an estimated $0.10 for commercial patients,
$0.06 for Medicare patients, and $0.07 for Medicaid plans (Baker et al., 2017). However,
costs for providing tobacco cessation services are not limited to medication. The cost for
delivering counseling and follow up calls should also be considered. In a cost analysis of
a hospital-based tobacco cessation intervention for smokers with chronic diseases,
Mullen et al. (2015) demonstrated that delivery of the Ottowa Model for Smoking
Cessation was cost effective and resulted in decreased hospitalizations and deaths for
smokers with chronic diseases. Cartmell et al. (2018), in an intervention of tobacco
dependence treatment service (TDTS) on readmission rates in patients with chronic
diseases, showed decreased readmission rates in smokers who had TDTS at 30 days. The
results of these studies demonstrate that positive benefits are conferred from tobacco
cessation programs for smokers, including cost effectiveness. Lightwood & Glantz
(2016), concluded that a 10% relative drop in smoking in each state would result in an
approximately $63 billion reduction in 2012 US health dollars the next year. While the
results of this small study are very limited, medical care costs would be reduced if
patients experience remission at first-line treatment and not have to undergo costly

106

PRELIMINARY REPORT OF COST

second-line and third-line treatment for cancer. Although the results of our study are not
generalizable due to very limited data, the well-documented adverse sequelae of tobacco
use along with prior research showing the benefits of tobacco cessation services further
emphasizes that tobacco cessation should be addressed at every visit, thereby optimizing
medical care in terms of cost savings and best care practices.
Limitations
Our study was limited by a small sample size. There were only 72 patients who
experienced first-line chemotherapy, and only 13 of them progressed to second-line
chemotherapy treatment. At the initiation of the original study, we had anticipated that
more patients would progress through treatment in order to be able to obtain
generalizable results. Still, the questions raised while conducting the study helped
develop questions for future research. A final limitation was that smoking status was
based on self-report, and not verified by cotinine analysis, which may limit smoking
status accuracy.
Although a retrospective data analysis of electronic medical records is often
utilized to provide an opportunity for data collection, there are disadvantages to review of
secondary data. Demographic data are limited, and these data were collected from a
single CC.
Conclusion
Our study provided a preliminary cost description of the cost of first- and secondline chemotherapy evaluate the overall cost of second-line and third-line chemotherapy in
patients with lung cancer. The current body of research would be enhanced by a study
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that involved a larger number of patients and included indirect costs such as
administration of the medication or hospital stays for side effect related toxicities.
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Table 1. Characteristics of Participants Receiving First-Line Chemotherapy

Characteristic Current Smoker Former Smoker Never Smoker
(n = 29)
(n = 35)
(n = 8)
Age (y), SD
61.7 +/- 10.7
68.6 +/- 7.0
59.7 +/- 7.7
White
Non-White
Male
Female
Married
Not married

19 (65%)
10 (35%)
16 (55%)
13 (45%)
20 (69%)
9 (31%)

21 (60%)
14 (40%)
17 (48%)
18 (51%)
21 (60%)
14 (40%)

6 (75%)
2 (25%)
1 (13%)
7 (87%)
7 (87%)
1 (13%)

Table 2. Characteristics of Participants Receiving Second-Line Chemotherapy

Characteristic Current Smoker Former Smoker Never Smoker
(n = 7)
(n = 1)
(n = 5)
Age (y), SD
63.1 +/- 10.4
65
58.4 +/- 9.0
White
Non-White
Male
Female
Married
Not married

5 (71%)
2 (29%)
3 (43%)
4 (57%)
4 (57%)
3(43%)

0
1 (100%)
0
1 (100%)
0
1 (100%)

4 (80%)
1 (20%)
1 (20%)
4 (80%)
5 (100%)
0
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Table 3. Mean Cost of Chemotherapy for First-Line and Second-Line Chemotherapy by
Smoking Status

Characteristic

First-line chemotherapy
(n = 72)

Second-line chemotherapy
(n = 13)

Current Smoker
(n=35)

M = $7512

M = $625

Former Smoker
(n=29)

M = $8711

M = $12

Never Smoker
(n=8)

M = $12982

M - $1755
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Table 4. Cost of Second-Line Therapy
Case

Treatment line

1

Second line

2
3
4
5
6
7
8
9

Second line
Second line
Second line
Second line
Second line
Second line
Second line
Second line

10
11

Second line
Second line

12

Second line

13

Second line

Medication and Number of
Cycles/Total Cost
carboplatin / pemetrexed b
intravenously (1 cycle)
docetaxel b (4 cycles)
nivolumab b (3 cycles)
docetaxel 135 mg b (2 cycles)
crizotinib 250 mgc PO
cisplatin/etoposide b (2 cycles)
nivolumabb (3 cycles)
cisplatin/etoposideb (2 cycles)
carboplatin/paclitaxelb (one
cycle) and then
carboplatin/gemcitabined (5
cycles)
paclitaxel 440 mg b (1 cycle)
carboplatin/pemetrexed b (3
cycles)
carboplatin/etoposide b (4
cycles)
carboplatin/gemcitabine b (2
cycles)

a based on Average Wholesale Price
b medication administered intravenously
c oral medication
d allergic to first agent

Never
Smoked

Formerly
Smoked

Current
Smoker
$8,084.28
$7,680.00
$18,600.00

$3,842.00
$19,266.97
$106.74
$22,319.97
$106.47
$219.60
$885.00

$220.80
$17,030.28
$282.96
$453.68
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Summary
This dissertation consists of three manuscripts that focus on interrelated aspects of
interventions targeted on tobacco cessation for people with cancer. The first manuscript
describes a systematic review of tobacco cessation services in inpatient and outpatient
settings in the United States (US), which was conducted to evaluate the effect of tobacco
cessation interventions for patients with cancer. The second and third manuscripts
describe the results of a retrospective data analysis of patients at a southeastern
university-affiliated cancer center (CC). The second study was conducted to determine if
there was an association between patients’ smoking status and treatment progression and
side effects in a cohort of never, former, and current smokers; the third manuscript
provides a preliminary report of second-line chemotherapy costs. The overarching theme
of the compendium is to offer a preliminary basis on which to evaluate tobacco cessation
interventions proven to be beneficial in smokers with lung cancer, and to determine
whether current smokers proceed through additional courses of treatment or require more
expensive treatment than their cohorts of former or never smokers. The findings, if
positive, would enhance existing literature suggesting that provision of tobacco cessation
services to oncology patients is beneficial in terms of outcomes and cost savings
(USDHHS, 2014).
The systematic review (manuscript 1) demonstrates that findings across most of
the studies (n=9) reflected a positive direction of effects pertaining to tobacco cessation
interventions for patients with cancer in the US. The impact of these programs included:
However, study sample sizes were small and lacked statistical significance. The results of
the systematic review regarding tobacco cessation interventions’ impact on patients are
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congruent with similar pooled meta-analyses of smaller studies conducted globally in the
same oncology population (Nayan, 2013; Nayan, 2011). Despite the lack of statistically
significant efforts in the oncology population, studies in the larger population of patients
who use tobacco have shown promise, particularly in the hospital setting. Rigotti et al.
(2008), in a meta-analysis of 33 trials, demonstrated that when smoking cessation
counseling was offered during hospitalization to patients who smoked, when follow-up
contacts continued for greater than a 1 month period after discharge, smoking cessation
rates were increased at 6 months and 12 months, as long as contacts continued after
discharge (pooled odds ratio [OR], 1.65; 95% CI, 1.44-1.90).
However, a question remains as to whether results of studies of chronically ill,
non-oncology smokers can be generalized to the population of patients with cancer who
smoke. Although studies in smokers with non-smoking related cancers (such as breast
cancer) have shown higher quit rates than in the general smoking population (Westmaas
et al., 2015), patients with smoking-related cancers and who continue to smoke may
comprise a more challenging population. In addition to a high recidivism rate, smokers
with cancer may face stigma from providers that adversely affect health outcomes
(Luberto, Hyland, Streck, Temel, and Park, 2016; Simmons et al, 2013). Using a teambased approach as espoused by Rigotti (2015), which encourages assessment of smoking
status and counseling combined with a combination of appropriate pharmacological
therapies and with regular follow-up visits, may prove beneficial with future
interventions in the oncology population.
In our study that reviewed treatment progression in patients by smoking status and
preliminary costs, the largest limitation was that treatment progression and disease
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progression were found, after the study, to be likely separate entities. Although a patient
could have undergone progression through multiple treatments due to disease
progression, it would not have necessarily reflected the true trajectory of the patient’s
course of illness. For example, a current smoker that did not undergo treatment
progression may have been too ill due to disease progression to undergo further
treatments. Alternately, patients who never smoked may have had the mental and
physical stamina to progress through more courses of treatment. We also did not have a
large group of never smokers with lung cancer and thus did not have enough participants
to achieve statistical power in this study. However, although this small study contained
several limitations, it was one of the first to begin to explore whether certain groups as
categorized by smoking status progressed in treatment. There are several opportunities
for future studies which continue this research. A qualitative component would be helpful
to add in order to elucidate the lived experiences of smokers with a tobacco-related
cancer to help determine what affected their decision to stop or continue treatment. This
exploratory analysis would be well-suited if expanded to quantify disease progression
more discretely, as well as continue to examine treatment progression for a longer period
of 3 to 5 years.
.
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